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Summary 
In this thesis we investigated maintenance requirements of Salmonella during chronic 
infections, and determined the relevant antigen properties that might facilitate the 
development of Salmonella vaccines. Overall, we wanted to achieve two goals: 
a) To identify suitable targets to eradicate persisting Salmonella.
b) Identify antigen properties for developing enteric fever vaccine.
To achieve the first goal we established a practical Salmonella mouse infection model 
for identifying bacterial maintenance functions essential for persistency.Using this 
model, we evaluated twelve Salmonella defects. Our data revealed extremely relaxed 
environment of Salmonella during persistency compared to the acute infection. On the 
other hand, we identified that unsatuarated/ cyclopropane fatty acid synthesis pathway 
might contain suitable targets for antimicrobial chemotherapy of chronic infections. 
To achieve the second goal, we tested thirty seven in vivo expressed antigens for 
immunogenicity and protectivity in a mouse typhoid fever model. We identified novel 
Salmonella antigens that conferred partial protection against virulent Salmonella in a 
typhoid fever model. The identified antigens had high sequence conservation among 
several Salmonella serovars suggesting that these antigens might be suitable as 
vaccine candidates against systemic Salmonella infection caused by diverse serovars. 
Using model antigens expressed in Salmonella and autologous antigens, our data also 
revealed that surface associated antigens might be promising for inducing both 
humoral and cellular immunity to Salmonella, as recognition of such antigens might 
enable uniquely detection and destruction of live Salmonella. This may provide a 
strategy to discover additional protective antigens for Salmonella and other 
intracellular pathogens.
Introduction 
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1. Introduction
The introduction of the thesis is divided into three parts (Part A, Part B, and Part C).
Part A:  General introduction to the Salmonella diseases (refer to section 1.1).
Part B: Mostly focuses on chronic Salmonella infections (refer to section 1.2).
Part C:  Prevention and effective control of Salmonella diseases through vaccination 
with more focus on the urgent need for a new enteric fever vaccine 
(refer to section 1.3) 
Introduction 
Part A –  Salmonella diseases
Introduction-Part A- Salmonella diseases 
4
1.1 Salmonella diseases 
Enteric fever, an inclusive term for typhoid and paratyphoid fever is a human - 
restricted systemic infection caused by Salmonella enterica serovar Typhi (S. typhi)
and serovar paratyphi (S. paratyphi A, B, and C). Unlike enteric fever, there are also a 
range of other clinical syndromes, including diarrhoeal disease caused by non - 
typhoidal Salmonella (NTS) that have a broad vertebrate host range. These organisms 
are the important causes of febrile illness where overcrowding, poor sanitation, and 
untreated water are the norm [1-4]. 
1.1.1 Global disease burden of Salmonella infections 
It was estimated in the year 2000 that typhoid fever caused 21.7 million illnesses and 
217,000 deaths and paratyphoid fever 5.4 million illnesses worldwide [2, 5]. In the 
United States and Europe, typhoid fever was the major cause of morbidity and 
mortality in the 19th century [6]. With the provision of good sewage systems and clean
water, there has been a dramatic decrease in the incidence of typhoid fever in these 
regions. But, enteric fever still remains a public health problem in developing 
countries [7]. In Asia, recently a large population- based prospective study confirmed 
the high incidence rate of typhoid fever in China, India, Indonesia, Pakistan, and 
Vietnam amongst children and adolescents (Fig 1) [8]. 
Outbreaks of typhoid fever are frequently reported from sub –Saharan Africa with 
large number of patients presenting with intestinal perforations [9]. 
Currently, serovars of Salmonella other than S. typhi have been emerging as causes of 
the disease and mortality in various sub continents of the world [10, 11].  In a number 
of Asian countries, S. paratyphi A appeared to be responsible for a growing 
proportion of enteric fever, sometimes accounting for 50% of Salmonella bloodstream 
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isolates from enteric fever patients. In addition, NTS that had previously been 
associated mostly with diarrhoea increasingly causes bacteraemia and focal infections 
especially in sub-Saharan African countries [12, 13]. Distinct strains of serovar 
Typhimurium are associated with this emerging disease. In a current study, two main 
Salmonella enterica serovars, S. typhimurium and S. enteritidis were isolated from 
patients of NTS bacteraemia and gastroenteritis [13, 14]. Overall, this trend raises 
serious concerns about the impact of enteric fever and failures of control strategies 
[15, 16].
Figure 1. World map representing countries endemic for typhoid (WHO, 2009). 
1.1.2 Symptoms, transmission and pathogenesis 
The clinical symptom of typhoid fever includes diarrhoea, sustained fever, headache,
malaise, and anorexia [17]. Approximately, 20% - 30% of patients develop rose spots 
on abdomen and chests [18]. Finally, gastrointestinal bleeding or perforations are 
usually observed during the third week of illness, but they may occur at any time. 
Other complications include abdominal pain, bloody stools, cholecystitis, and rarely 
pancreatitis [16, 19, 20]. The severity of the illness mainly depends on 
Introduction-Part A- Salmonella diseases 
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immunocompetence, age, virulence of the S. typhi strain, and nutritional status of the 
patient [17]. Approximately, 1% to 4% of the patients become chronic carriers and 
shed Salmonella for years [21].  The chronic carriers of S. typhi although are highly 
contagious, but remain typically asymptomatic, making the identification of carriers 
difficult [22, 23]. 
The only source of S. typhi infections are humans, there are no animal reservoirs. The 
organisms are mostly shed in the stool and urine. The infection is mainly spread via 
the faecal – oral route through water or food that has been contaminated by a person 
with acute disease or, an asymptomatic chronic carrier [17, 24]. The chronic carriers 
form a reservoir for further spread of the disease through bacterial shedding in urine 
and faeces [21, 25]. 
Salmonella are introduced into the gastrointestinal tract by ingestion of contaminated 
food or water (Fig 2). The infection dose has been estimated to be 105 to 109
organisms [21, 26].  A certain percentage of the bacteria survive the acidic barrier in 
the stomach, and are internalized by the M cells (microfold epithelial cells) overlying 
the Peyer’s patches in the small intestine. The organisms are then transported to the 
lymphoid tissue including the mesenteric lymph node. Salmonella may gain entrance 
into the bloodstream directly, or via the thoracic duct [21, 26, 27]. The incubation 
period is approximately 7 – 14 days [21]. The bacteria then disseminates through the 
bloodstream and lymphatics systematically to colonize liver, spleen, gall bladder, and 
bone marrow. Infection of the gall bladder followed by biofilm formation on the 
gallstones contributes to the asymptomatic carrier state. The carriers continue to 
periodically discharge Salmonella from the gall bladder and infect new hosts. 
                                                                                     Introduction-Part A- Salmonella diseases                                 
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Figure 2.  Salmonella infection cycle and persistence mechanism [28]. 
 
1.1.3 History of the disease burden 
From the late 1800s to 1949, typhoid fever caused by S. typhi was one of the most 
serious health problems in the United States. Between 1895 and 1910, Philadelphia 
experienced three typhoid fever epidemics due to unfiltered water supplies [29]. 
European countries have also experienced endemic outbreaks of typhoid fever. In 
1964, there were 507 cases of typhoid fever in Scotland from canned Argentenian 
corned beef that was cooled in contaminated river water. A 1998 Danish outbreak and 
1997 French outbreak of multiresistant S. typhi were linked to the ingestion of 
contaminated pork [30, 31]. Over the past centuries, improvements in water treatment, 
sanitation, and food handling practices has led to the dramatic fall in the incidence of 
typhoid fever in the developed countries [21, 32]. 
                                                                                     Introduction-Part A- Salmonella diseases                                 
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Despite the availability of clean water, still in 1900 typhoid fever claimed the lives of 
20,000 Americans in locations where the drinking water was known to be pure[33]. 
The reason were chronic carriers such as a woman named Mary Mallon, better known 
as “Typhoid Mary”, the first healthy S. typhi carrier to be identified and charted in 
North America. An Irish born cook, who didn’t have any signs of the disease, 
continued to infect the wealthy New York citizens to whom she provided her culinary 
services[34]. 
1.1.4 Current problems with the disease control 
 
Although there are indications of an overall downward trend in the global incidence 
of typhoid, enteric fever continues to remain a major public health challenge in the 
developing countries [35].  
One of the public health concerns in these countries is the overcrowded slums that 
have poor waste disposal and drainage facilities. Due, to poor sanitation conditions, 
contaminated food and water is common in these communities resulting in typhoid 
fever [36]. Secondly, knowledge about typhoid fever is still limited in the 
economically disadvantaged countries. Often half–measures are taken by self-
medications to avoid the unaffordable costs of modern healthcare leading to 
misdiagnosis of the disease[37]. Thirdly, Multidrug-resistant (MDR) strains of S. 
typhi has also become a challenge in the management of typhoid fever in these 
endemic locations. Resistance has been noticed to all suitable drugs including 
trimethoprim, ampicillin, quinolones, and cephalosporins with increasing rates[35]. 
Upto 60% of Salmonella strains isolated exhibit multidrug resistance to almost every 
available first – line antibiotics.  
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 Finally, despite the availability of several licensed vaccines, the use of these vaccines 
in endemic areas has not been as extensive as it should be resulting in the 
mismanagement of the disease burden [35]. 
1.1.5 Diagnosis and treatment of Salmonella infections 
Diagnosing typhoid fever is difficult because the symptoms and signs overlap with 
other common febrile illness. After the first week of illness, stool and urine cultures 
may be positive however these cultures cannot distinguish acute disease from a carrier 
state [17, 38]. The antibiotic of choice for treating active typhoid fever is the 
fluoroquinolone ciprofloxacin. The drug regimen is for 7 – 10 days and has a high 
cure rate. Other quinolones including ofloxacin, norfloxacin, or levofloxacin and third 
generation cephalosporins can also be used [39-41].  
Fortunately, with adequate treatment, most of the patients recover from the acute 
phase of typhoid but the treatment of a chronic carrier is very difficult [42, 43]. The 
impact of high incidence rate of typhoid fever in many parts of the world highlights 
the importance of understanding the mechanisms of persistent Salmonella infection 
[21]. The S. typhi carrier state must be completely eradicated as it is the main reason 
for continuous transmission of the pathogen.  
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1.2 Antimicrobial chemotherapy of chronic Salmonella infections 
1.2.1 Salmonella persistence as a problem 
Bacterial persistence is the phenomenon in which a small subpopulation of the cells 
survives antibiotic treatment (“tolerance”) [44]. In contrast to antibiotic resistance, 
persistent bacteria do not grow in presence of antibiotics and their tolerance arises 
from physiological processes rather than genetic mutations[45]. As a result, the 
antibiotics might not eradicate infections completely and the persistent bacteria could 
later cause relapse of the disease [46]. 
Epidemiological studies indicated that approximately 90% of chronically infected 
carriers have gall stones [47, 48].  The typhoid carrier state, both with and without 
gall stones, is implicated as a predisposing factor for the development of gall bladder 
cancer [21]. S. typhi forms biofilm on gall stones and antibiotic treatment has not 
proved to be effective in the resolution of chronic S. typhi colonization of gall bladder. 
The persisters are contained in the biofilm and can partially survive the antibiotic 
treatment. When the antibiotic therapy is discontinued, the persistent bacteria can 
repopulate the biofilm, producing relapse of the infection (Fig 3) [44, 49]. 
For patients with gall stones, cholecystectomy (complete removal of the gall bladder) 
increases the cure rate, but does not guarantee the eradication of the carrier state[44].
In addition, chronic Salmonella carriers should be treated by a four week course of a 
quinolone such as ciprofloxacin[50]. The long term chemotherapy results in poor 
patient compliance, and inability to eradicate the carrier state. Persisters, likely to be 
responsible for chronic infections, can be suppressed but cannot be always completely 
eliminated with the existing antimicrobials[44]. 
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Figure 3. Treatment of biofilm with antibiotics. Initial antibiotic treatment kills most cells (green) in 
both the biofilm and planktonic populations. The immune system eradicates planktonic persisters  but 
the biofilm persisters (pink) continue to stay protected within the exopolymer matrix and escape 
clearance by the host defense systems. After the discontinuation of the antibiotic therapy, the persisters 
repopulate the biofilm and the infection relapses. Adapted from [51]. 
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1.2.1.1 Mechanisms of tolerance versus resistance to bactericidal antibiotics 
Persisters often represent small subpopulation of cells that spontaneously enter a 
dormant, non-dividing state that is tolerant to most antibiotics [44]. Antibiotic 
tolerance might function by preventing target corruption by an antibiotic through 
blocking its target. If the persisters are dormant and do not have topoisomerase or 
translation activity, or have no or little cell wall synthesis, then the antibiotics will 
bind to, but will not be able to corrupt, the function of respective target molecule  
(Fig 4) [51].  
In contrast to antibiotic tolerance, resistance represents the ability of cells to grow in 
presence of antibiotics [44]. Different types of resistance mechanisms include 
antibiotic modification/destruction by specialized enzymatic reactions, target 
modification by mutation, restricted permeability to antibiotics, antibiotic efflux, and 
target substitution [52, 53]  . All of these mechanisms limit antibiotic efficacy and 
allow bacteria to grow even at an elevated concentration of antibiotics [51]. 
 
Figure 4. Tolerance versus resistance to antibiotics.  a) The antibiotic (pink) binds to the target 
(green) altering its function, which causes cell death. b) The target of the antibiotic has been modified 
so that it’s unable to bind the antibiotic and the cells become resistant to treatment with the drug.  
+ 
+ 
+ 
Cell death 
Antibiotic 
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c) 
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c) The antibiotic target is inhibited by a different molecule (orange). This prevents the antibiotic from 
disrupting its function, resulting in tolerance. Adapted from [51].  
1.2.2 General mechanisms of persistency 
Persistency refers to the clinical observation of the infection without apparent disease.  
 It is very difficult to study persistency, because the bacteria are inaccessible and 
problematic to visualize in humans. Instead much research has been focused on a 
bacterial phenotype – dormancy. 
 The term dormancy has been much debated. Generally, dormancy is defined as a 
stable but reversible, non-replicating state. However, this definition covers a broad 
range of phenotypes that has been observed in bacteria as explained below (a,b,c): 
 a) In case of some bacteria, there are in vitro conditions that restrict replication, but 
allow the bacteria to remain culturable under standard conditions[54].  
b) Some species can form spores, making them metabolically inactive and extremely 
resistant to environmental stresses [54].  
c) In some cases, prolonged cultures induce a state where bacteria remain viable but 
non culturable (VBNC) unless they are resuscitated with the addition of exogenous 
factors [54].  
Since, some of these phenotypes were observed in the persistent bacteria several 
researchers consider persisters as the dormant variants of regular cells [44]. 
However, another persistence strategy was proposed by Munoz Elias et al in M. 
tuberculosis. In chronically infected mice, persistent bacteria might represent a static 
equilibrium in which the bacterial cell division is very slow or non-existent [55]. 
This widespread notion that chronic tuberculosis is in static equilibrium, was 
completely contradicted by another study. The data showed that persistent M. 
tuberculsosis represents a dynamic equilibrium where the bacterial replication is 
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balanced by an equally rapid host mediated killing, thus maintaining steady tissue 
loads [56]. 
It is difficult to understand which of these states is relevant in human disease. 
Predominantly, for simplicity it has been mostly assumed that persisters might be 
dormant cells and due to nutrient and other limitations, do not metabolize and 
replicate sufficiently for the antimicrobials to function effectively. 
Different mechanisms have been proposed for persister cell formation. A combination 
of deterministic and stochastic events is thought to give rise to persisters in a bacterial 
population [57-59]. This can happen through redundant independent mechanisms such 
as induction of TA (toxin antitoxin) modules [60, 61] and/or SOS stress responses 
[62, 63] . 
Whatever the mechanism of persister formation, to eradicate the persistent bacteria it 
would be necessary to identify the “Achilles heel” of persisters – the essential 
maintenance functions required to survive within the host [44]. It is possible that there 
is actually no such “achilles heel”, as completely dormant bacteria might lack any 
maintenance requirements but just survive without any activity.  
1.2.3 Models for studying persisting pathogens 
 Critical maintenance requirements during persistency can be identified using gene 
deletion mutants in a well validated model. Various in vitro and in vivo models have 
been established to study the chronic infection of different pathogens. The important 
criteria for such models are their practicality, and their ability to closely mimic 
relevant in vivo conditions. The hypoxia [64] and nutrient starvation [65] models of 
latent tuberculosis are well studied and elucidated. However, these models are 
probably still far from the human granuloma conditions. The hypoxia induced model 
captures the hypoxic nature of the granuloma, but lacks the effect of macrophage 
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phagocytosis, immune response, and eventual release to the extracellular milieu. The 
nutrient starvation models are not hypoxic and it is unlikely that the host environment 
in which M. tuberculosis persists will be limiting of all nutrients [66].  
Another model, the in vitro drug - tolerant phenotype that occurs in static 100–day  
old stationary phase M. tuberculosis cultures is worth mentioning. It has been used for 
screening new drugs that might be active against drug–tolerant microorganisms [67, 
68]. However, the relationship between the bacteria in human TB lesions and the 
metabolic state of bacteria in the model has not been validated. So, none of the above 
mentioned in vitro models fully capture the complex heterogeneous of granuloma 
with a gradient of oxygenation and nutrients [69]. 
In vivo models might be more useful for analyzing persister maintenance 
requirements. Two mouse models have been studied in M. tuberculosis. In the first 
model, the termination of the growth of the bacilli coincides with the onset of host 
immune response (The Untreated Mouse model) [70, 71]. In the second one, chronic 
infection is established by administering antimicrobial drug combination (The Drug – 
Induced Cornell mouse model) [70, 72]. However, the granulomas that develop in 
mice are not well formed structures like human lesions [66, 73]. 
Several rodent models have been established to study E. faecalis persistency. But, the 
experimental conditions defined by these models are inadequate for investigation of 
persistency, since the bacteria are readily cleared and fail to establish chronic cystitis. 
These models fail to provide changes in bladder homeostasis following urinary 
catheterization to achieve successful infection of the urinary tract [74-77]. 
To study S. typhimurium persistence, a Nramp1r mouse model was established. 
Nramp 1 is a natural resistance associated macrophage protein that localizes to the 
membrane of Salmonella containing vacuole, removes cations from the vacuole and in 
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turn controls the replication of intracellular bacteria [78]. In these mice, an initial 
acute disease (approximately 2 weeks) is followed by chronic infection. A microarray 
– based negative screen was performed to identify S. typhimurium genes that 
contribute to persistency in Nramp1r mouse. A transposon - mutagenized library was 
used to infect mice intraperitoneally, and the disappearance of the mutants was 
monitored after 7, 14, 21, and 28 days post infection.  
Most of the SPI 1 and SPI 2 (Salmonella pathogenecity island 1 and 2, which encodes 
for type III secretion, system) genes were required by Salmonella for systemic 
persistence. However, the contribution of many genes during persistent infection 
could not be analyzed as corresponding mutants already dropped out during the initial 
acute infection. Moreover, the final time point (day 49) that is the actual persistent 
stage, had to be removed from further analysis because the bacterial loads in spleen 
and liver were too small [79].  
Taken together, despite considerable effort practical in vivo models are still largely 
lacking. There is thus a need to establish persistency in vivo models for identifying 
genes crucial for chronic phase survival that could be targeted for therapy. 
1.2.4 Potential mechanisms of persistency in other pathogens 
Although a well validated model is largely lacking yet, several individual 
maintenance function requirements during persistency have been proposed in various 
pathogens. It has been suggested that during persistent state, Mycobacterium 
tuberculosis performs limited protein synthesis, but may need to spend its available 
resources on maintaining cell wall, genome integrity, and membrane potential as well 
as resisting host defense. Studies indicate that de novo ATP synthesis is required for 
the viability of hypoxic non replicating mycobacteria [80]. In vitro data also 
suggested that expression of ribonucleotide reductase (encoded by nrdZ) was 
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upregulated indicating that a pool of deoxyribonucleotides is required either for the 
process of DNA repair or maintenance of chromosomal integrity during M. 
tuberculosis persistency [73, 81]. However, in infected mice this mutant had no 
apparent virulence defect [81]. Even polyphosphate metabolism seemed to be crucial 
in metabolic adaptation for survival in the in vitro models of Mtb persistency [82].  
In E. coli, degradation of membrane phospholipids is important for persistent bacteria. 
The FadR regulon involved in fatty acid β – oxidation pathway seemed to provide the 
persistent bacteria with endogenous carbon and energy from the membrane derived 
fatty acids [44].  
Recent data in E. coli also suggests that ATP generation through TCA cycle is crucial 
for persistency [83]. On the other hand, this result was in apparent contradiction to 
another study showing that decrease in ATP levels in E. coli sends cells into 
dormancy [44]. Hence, this reflects that data obtained using different model system 
shows differential perturbation effects. 
 Most of these pathways discussed above were identified in in vitro models and it is 
unclear if relevant host microenvironments in which the pathogen persists will be 
actually limiting for nutrients [81]. So, all these data needs to be validated in vivo to 
understand the actual maintenance requirements. 
In vivo data showed that nitrate reductase (encoded by narGHJI genes) activity is 
required for maintaining redox balance in M. bovis during persistency. But, it is not 
clear why nitrate reductase activity is required for virulence in lung, liver, kidney, and 
not in spleen in SCID (severe combined immunodeficiency) mice [84]. 
 Taken together, all these different studies reflect that maintenance function 
requirements to survive during persistency might be different for each pathogen.  
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Identifying such basal maintenance activities could represent attractive targets for 
therapy of chronic infections.  
1.2.5 Goal and aims of the first part of thesis 
Goal 
The overall goal for this part of the thesis was to identify suitable targets to eradicate 
persisting Salmonella.
Aims 
To achieve this goal I followed several specific aims: 
a) Generate a relevant Salmonella persistency model that is practical, and mimic
the in vivo conditions (refer to section 2.1). 
b) Experimental testing of candidate target genes against persistent Salmonella
infection (refer to section 2.1). 
c) Deduce general properties of Salmonella persistency (refer to section 2.1).
Introduction 
Part C – Prevention and effective control of 
Salmonella diseases 
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1.3 Prevention and effective control of Salmonella diseases 
Public awareness regarding proper food preparation, hand washing, safe water supply, 
and control of flies is essential for preventing typhoid fever. Also typhoid carriers 
must be excluded from handling food and caring for patients as an additional measure 
of the prevention strategy [17]. 
To further reduce the impact of typhoid fever efficacious vaccines are needed (Fig 5). 
Vaccination is considered as the most cost–effective tool for the prevention of 
infectious diseases, and could offer long term solution against infection. 
Figure 5. Time course of immune response after vaccination that leads to the formation and 
maintenance of active immunological memory. 
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1.3.1 Currently available vaccines and their disadvantages 
Different approaches have been pursued to develop vaccines against typhoid fever. 
This includes inactivated whole cell vaccines, live attenuated vaccines or subunit 
vaccines (Table 1) 
Ty21a vaccine Vi polysaccharide
vaccine
Vi conjugate
vaccine
Type Live Subunit Subunit
Route of
Administration
Oral IM/SC IM/SC
Doses/regimen 3 1 1-3
Revaccination 5-7 years 3 years Min 4y-max life
Efficacy 50-80% 50-80% Upto 90%
Duration of
Efficacy
62% at 7 years 55% at 3 years 90%
Cross protection
against paratyphoid,
NTS
Yes No No
Table 1. Characteristics of current typhoid fever vaccine. Adapted from [5]. 
1.3.1.1 Inactivated whole cell vaccines 
The parenteral whole cell typhoid vaccines were obtained by inactivating virulent 
microorganisms with heat or chemicals. The first typhoid vaccine mainly consisted of 
inactivated S. typhi by heat and phenol or by acetone [85]. Its protection efficacy 
ranged from 51% to 88% in children and young adults and the effect lasted up to 7 
years [86-88]. These parenteral vaccines containing mixture of different serovars were 
able to confer broad protection against typhoid fever. However, their global use for 
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routine vaccination was discontinued due to high reactogenicity. It caused severe local 
pain (upto 35% of the recipients), headache (10%) and fever (6 – 30%) after 
immunization [28, 89]. Hence, the whole cell vaccine was replaced by oral live 
attenuated, and Vi –based parenteral vaccines. 
1.3.1.2 S. typhi Ty21a live oral vaccine 
Ty21a is an attenuated mutant strain of S. typhi Ty2 that has a GalE-and Vi- negative 
phenotype [90]. Galactose residues are an important component of the smooth LPS 
O-antigen in S. typhi. When grown in absence of galactose, Ty21a expresses rough 
O-antigen and is non-immunogenic [91].  galE gene encodes for uridine diphosphate 
(UDP)–galactose–4–epimerase which is responsible for the conversion of 
UDP–glucose to UDP–galactose and vice versa. Due to deficiency of this enzyme, 
UDP galactose cannot be metabolized and accumulates in the cytoplasm causing cell 
lysis and attenuation [85]. Further spontaneous mutations in the via and ilvd genes 
resulted in the loss of Vi capsular polysaccharide, and an auxotrophic phenotype for 
isoleucine and valine repectively [92]. An additional mutation in the rpoS gene, 
inherited from the wild type parental Ty2 also contributed to the avirulence of the 
Ty21a strain [93]. Partly from the rpoS mutation, Ty21a has poor capacity to survive 
starvation conditions, and various environmental stresses [94].  
Ty21a vaccine induces strong CD4+ T helper type 1 and CD8+ T cell immune
response. Ty21a vaccine has excellent tolerability and protective efficacy of 67% - 
80% (applying three doses of enteric–coated capsule or liquid formulation). 
Ty21a has the drawbacks of requiring multiple doses and being cold–chain 
dependent, both factors that impairs its widespread use in endemic areas [85, 95].
Moreover, this vaccine cannot be used in children under 2 years of age, an age group 
that is significantly affected by the disease. It also has only moderate protection
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against S. paratyphi A, B, and NTS strains that were recently found to be associated 
with multidrug resistance [96]. 
1.3.1.3 Novel attenuated S. typhi strains
The need to administer multiple doses to elicit a protective immune response is 
viewed as a drawback of the Ty21a vaccine. So, novel attenuated S. typhi strains that 
may serve as a single dose, oral typhoid vaccines, were developed as an alternative to 
the Ty21a strain. 
The most extensively evaluated metabolically attenuated strains were mutants 
deficient in the biosynthesis of aromatic amino acids (aroA, or aroC, and aroD), and 
purines (purA, and purE). In the CVD 908 strain (Ty2 aroC aroD) mutation in the aro
genes lead to an auxotrophy for aromatic amino acid causing strong attenuation [85,
97]. Although this vaccine was well tolerated, and highly immunogenic, CVD 908 
resulted in silent vaccinemia (viable organisms in blood) in a proportion of subjects. 
Due to this reason, development of CVD 908 was discontinued [85, 98]. Other 
attenuated strains like aroC aroD derivative of the serovar typhi isolate ISP1820 
(strain CVD 906), and aroA aroD (strain PBCC211) or aroA aroD htrA (strain
PBCC222) derivatives of CDC10-80 were also found to cause vaccinemia, fever, and 
other adverse reactions [98]. The cya crp mutant also caused vaccinemia and adverse 
reactions [99]. More heavily attenuated strains were also tested but found to induce 
poor immune response in vaccinees (e.g pur and gua mutations) [100]. The general 
problem associated with the attenuated live bacterial vaccine is the frequent rate of 
shedding, and the risk of horizontal gene transfer [101]. Live attenuated Salmonella
vaccines like aroA mutants or htrA mutants caused lethal infections in mice deficient 
in T cells, IL-12, or IFN-γ. Therefore, live attenuated vaccines could be dangerous for 
immunocompromised individuals (HIV) [102].  
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The recently developed M01ZH09 (also referred to as ZH9) lacks the aroC and ssaV
(a key component of the SPI 2 type III secretion system machinery) genes. This strain 
was found to be safe and highly immunogenic in phase I clinical trial and is 
considered to be a future vaccine [103]. 
1.3.1.4  Vi – based subunit vaccine 
Compared to live attenuated vaccines, subunit vaccines contain only few, broadly 
conserved Salmonella components and cannot cause infection even in heavily 
immunocompromised individuals. 
The only currently used subunit vaccines contain purified Vi capsular polysaccharide 
of S. typhi. It consists of (α–1-4),2–deoxy–2–N–acetyl galacturonic acid, which is 
partially O–acetylated at carbon 3 and forms a capsule that protects the bacteria 
against lysis and phagocytosis [104, 105] . The protective efficacy of these vaccines is 
approximately 64% - 72% and lasts up to 17–21 months [85]. The most important 
drawback of simple Vi polysaccharide vaccines is its poor efficacy in infants and 
toddlers. And immune responses against polysaccharide donot involve T cells, so 
immunological memory was not established [106]. These limitations were recently 
overcome by linking T cell independent Vi polysaccharide antigen to a T–dependent
protein carrier molecule that resulted in T–dependent conjugate vaccine. For S. typhi 
conjugate vaccine, covalent binding of Vi polysaccharide to recombinant 
Pseudomonas aeruginosa exotoxin A elucidated higher and more sustained IgG
antibody response than pure Vi polysaccharide [106]. It also showed high 
seroconversion in vaccinees in endemic and non-endemic areas (a fourfold rise in 
anti – vi antibodies is defined as seroconversion) [107]. 
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However, S. paratyphi A and B, as well as NTS all lack the capsular Vi antigen. 
Therefore, the Vi polysaccharide vaccines is ineffective against these bacterial strains 
with rapidly increasing clinical importance. 
The limitations and drawbacks of all the available vaccines emphasize the urgent need 
of effective and affordable enteric fever vaccines with broad serovar coverage [108, 
85]. 
1.3.2 Immune response against Salmonella infection 
In order to design specific vaccination strategies against Salmonella, it is important to 
have an increasing knowledge on the functionality of the immune system and the cells 
involved in generation of an immune response. 
A schematic representation of infection with S. typhi in mice is shown in Fig 6. The 
innate immune response plays an essential role in the early response to Salmonella
infections. The initial stages of Salmonella infection are characterized by recruitment 
and activation of phagocytic macrophages and neutrophils [109]. This is followed by 
production of large amounts of proinflammatory cytokines (TNF–α, IL–1, IL– 6,
IL–8, IL–12, IFN–γ) as well as macrophage migration inhibitory factor, and iNOS 
[110, 111] by a variety of cells as a reaction to the toll receptors (flagellin, LPS, 
lipoproteins) and bacterial effectors of the type III secretion system [112, 113]. Due to 
this primary line of defense, many but not all Salmonella are eliminated [114]. 
For effective control and eradication of the bacteria from tissues, activation of 
acquired immunity through generation of Salmonella specific lymphocytes is essential
[109]. 
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1.3.2.1 Importance of T cells for immunity to Salmonella
Evidence for a crucial role of T cells is provided by the high susceptibility of mice 
deficient in αβ T cells [115] and HIV infected individuals with low CD4+ T cell
counts [116]. In most experiments, CD4+ T cells appeared more important than CD8+
T cells [115, 117]. Depletion of CD4+ T cells in mice had more pronounced effect on
the control of Salmonella infection, and also on protection induced by vaccination of 
attenuated S. typhimurium strain. Transfer of CD4+ T cells from vaccinated mice to
naive recipients resulted in better protection compared to transfer of CD8+ T cells
[115, 117, 118]. Additionally, mice deficient in MHC class II that are CD4+ T cells
deficient showed increased susceptibility to Salmonella, reflecting the crucial role of 
CD4+ T cells [119].
CD4+TH1 cells produce IFN–γ and TNF–α and activate cellular immunity, whereas
TH2 cells produce IL-4, IL–5, IL–13 that activate and differentiate B cells [114]. A 
number of studies indicated that Salmonella infection induces predominantly TH1
responses [118, 120]. Importantly, mice deficient for IFN–γ receptors are highly 
susceptible to Salmonella infection [119]. This supports the crucial role of CD4+ TH1
derived IFN–γ for immunity to Salmonella. 
1.3.2.2 Role of antibodies and B cells for immunity to Salmonella
During different stages of infection, antibodies can perform several functions of 
protection [109]. Evidence from humans and animal studies suggest that infection 
caused by non-typhoidal Salmonella causes severe bacteremia when specific 
antibodies from different B cell subsets are lacking [121]. Salmonella infection also 
results in potent antibody response particularly against LPS [122] but these are 
actually detrimental for protection. A recent study indicated that excess inhibitory 
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antibodies against Salmonella LPS resulted in impaired immunity against NTS 
bacteremia in HIV patients [123]. 
In the intestinal lumen, IgA and IgM antibodies could block penetration of 
Salmonella into deeper tissues. Injection of B cell hybridoma producing Salmonella 
specific IgA prevents against Salmonella oral infection in mice [124]. 
The contribution of B cells to Salmonella immunity has been always controversial 
providing conflicting results after induction of passive immunity by transfer of serum 
to naive mice [114]. But, a recent review stated that B cells and antibodies contribute 
to protection against secondary infection in mice and also in humans. For example, in 
vaccinated mice antibodies contribute to control in the very early stages of infection 
[125].  
Experiment with mice mutated in Igμ gene (Igh–6 -/-) which are deficient in B cells,
showed increased susceptibility to Salmonella infection and were unable to mount 
strong immune response when infected with S. typhimurium aroA vaccine [126]. This 
study indicated B cells are required for acquired resistance[114]. But, other than just 
producing Salmonella specific antibodies, B cells are also involved in the 
engenderment and expansion of anti–Salmonella Th1 cells. Further, work in chimeric 
mice also revealed the early (innate) and late (cognate) contributions of B cells to Th1 
programming [125, 127]. 
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Figure 6. Schematic representation of infection with S. typhi. Bacteria enter by invading M cells. 
This is followed by inflammation and phagocytosis of the bacteria by neutrophils, macrophages, and 
recruitment of T and B cells. Salmonella targets specific type of host cells like dendritic cells and/or 
macrophages that favors dissemination into deeper tissues (spleen, bone marrow, liver, gall bladder). 
Periodic reseeding of the mucosal surface via the bile duct takes place and shedding can occur from the 
mucosal surface. Adapted from [125].  
1.3.3 Antigen parameters important for generating protective immune responses 
It is clear that both humoral and cellular immune responses are important for 
protection against Salmonella infection [125]. In particular, CD4+T cells are crucial 
for immunity to Salmonella [128]. Unfortunately, only few antigens can be 
recognized by protective CD4+T cells, and their identification thus requires major 
resources. Identifying relevant antigen properties could help to narrow down the 
Limited luminal 
replication 
S. enterica typhi 
Shedding into 
lumen via bile 
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search to only the most promising candidates. Indeed, several criteria like sequence 
conservation across Salmonella serovars, in vivo expression, immunogenicity, and 
surface localization of the antigens have been put forward to prioritize candidates for 
novel antigen identification.  
High sequence conservation across different serovars of Salmonella could 
represent a potentially relevant antigen property especially to identify vaccine 
candidates with broad serovar coverage. The availability of complete genome 
sequences of microorganisms in combination with comparative genomics has helped 
to compare related bacterial pathogens and identify conserved genes amongst them. 
Indeed, this property was utilized for identifying protective antigens against Neisseria 
meningitides serogroup B [129].  
Expression of antigens during an infection could be another antigen property that 
can affect CD4+T cell responses. In vivo expression is essential for antigen 
recognition and protective immunity. The small minority of highly expressed antigens 
might be preferentially recognized by the host’s immune system, and testing of this 
small subset of attractive antigens could allow rapid identification of protective 
antigens [128]. In vivo expression can be deduced from several approaches like in 
vivo expression technology (IVET), signature–tagged mutagenesis (STM), differential 
fluorescence induction (DFI), in vivo induced antigen technology (IVIAT), and 
transcriptional and proteomic profiling [130, 131] . 
Other than antigen expression, antigen immunogenicity can be another prerequisite 
for an antigen to stimulate antibody and CD4+ T cells response. Sera from covalescent 
individuals who have survived infection can demonstrate the antigens that were 
expressed in vivo and recognized by the immune system. This can be deduced from 
approaches like Serological proteome analysis (SERPA). Interestingly, this approach 
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has been utilized to identify T and B cell antigens of Chlamydia trachomatis.
However, many immunodominant antigens in covalescent individuals lacks protective 
efficacy [132].  
Antigen localization is another antigen property that can affect CD4+T cell 
responses. Secreted or surface associated antigens might induce strong cellular 
immune response because of efficient antigen processing, and/or their association 
with classical inflammatory molecule lipopolysaccharide that provokes strong 
humoral and cellular immune response. Indeed, partially protective antigens FliC 
(flagella) and SseB (needle complex of type III secretion system) [128] are part of 
surface structures. Another surface protein, the outer membrane porin OmpD, might 
represent candidate vaccine target against non-typhoidal salmonellosis [121]. Recent 
reports have also indicated that antibodies against S. typhimurium other outer 
membrane proteins (OmpF, OmpC) might protect against Salmonella in the mouse 
model [123]. 
However, evidence supporting the relevance of all these antigen properties is still 
rather weak because antigens with different properties have not yet been 
systematically compared in immunization experiments. 
If relevant antigen properties would be known, then reverse vaccinology could be 
employed as a fast way of identifying protective antigens (Fig 7). This genome based 
approach uses in silico tools to predict novel antigens based on criteria such as 
predicted localization from the genome sequence of the bacteria, virus, or pathogen of 
interest and subsequently confirming their activity by experimental biology [133,
134]. 
Areas in reverse vaccinology such as functional (transcriptomics and proteomics) 
genomics, structural genomics have the potential to identify promising vaccine 
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candidates based on antigen properties like in vivo expression level, and/or 
localization from the transcription, and expression profiles of the selected 
antigens/proteins. 
Pan–genomic reverse vaccinology, comparative genomics, immunoinformatics can 
predict novel candidates based on criteria like high sequence conservation from the 
genome sequence of the pathogens [133]. 
But till date, reverse vaccinology has been useful for identifying vaccine candidates 
that induces serum antibodies and B cells. Identification of T cell antigens has been 
technically challenging, and has not been readily feasible with this approach because 
relevant antigen properties for candidate selection are unclear [133]. 
Figure 7. Comparison of conventional vaccinology with reverse vaccinology. Schematic 
Figure 7. Comparison of conventional vaccinology with reverse vaccinology. Schematic 
representation showing different steps from in silico analysis to vaccine development in reverse
vaccinology[135]. 
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1.3.4 Goal and aims of the second part of thesis 
Goal 
None of the currently available licensed vaccines protect against all important 
serovars of Salmonella, and all of these vaccines also have other limitations. For 
developing novel vaccines, identifying protective antigens is an important bottleneck. 
Unraveling antigen properties that are important for generating protective immune 
response might help to more efficiently identify the rare suitable antigens. So, the goal 
of this part of the thesis was to identify predictive antigen properties that could help to 
develop a safe, enteric fever vaccine with broad serovar coverage. 
Aims 
To achieve this goal, two specific aims were followed: 
a) Comparison of diverse Salmonella antigens in immunization/challenge
experiments (refer to section 2.2). 
b) Identification of relevant antigen properties that might be predictive for
protectivity (refer to section 2.2). 
Results 
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2. Results
The results section is divided into two parts (Part A and Part B). 
Part A: Research Publication I – Extensive in vivo resilience of persisting Salmonella 
(refer to section 2.1).
Part B: Research Publication II – Immunity to intracellular Salmonella depends on 
surface associated antigens (refer to section 2.2). 
Results 
Part A – Extensive in vivo resilience of 
persisting Salmonella 
Results-Part A-Publication I 
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2.1 Extensive in vivo resilience of persistent Salmonella
PloS one, 2012, 7(7), e42007
Somedutta Barat, Benjamin Steeb,Alain Maźe, Dirk Bumann. 
2.1.1 Abstract 
Chronic infections caused by persisting pathogens represent a tremendous health 
problem throughout the world. Such infections are often difficult to treat because it is 
largely unknown whether the persisters have any maintenance requirements for 
survival. We have established a simple, practical, and stringent mouse model to 
identify Salmonella maintenance functions that are essential for persistency. Our data 
revealed extremely relaxed requirements for Salmonella during persistency compared 
to acute infection. Only inactive biosynthesis of unsaturated/cyclopropane fatty acid 
resulted in clearance to non-detectable tissue loads within few days. This clearance 
kinetics was faster compared to the currently recommended antimicrobial drug 
enrofloxacin for chronic salmonellosis suggesting that unsaturated/cyclopropane fatty 
acid pathway might contain suitable targets to treat chronic Salmonella infections.   
Statement of my work 
I contributed to this work by generating all the data in the figures except the in silico
analysis. 
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Chronic infections caused by persistent pathogens represent an important health problem. Here, we establish a simple
practical mouse Salmonella infection model for identifying bacterial maintenance functions that are essential for
persistency. In this model, a substantial fraction of Salmonella survived even several days of treatment with a potent
fluoroquinolone antibiotic indicating stringency of the model. Evaluation of twelve metabolic defects revealed dramatically
different requirements for Salmonella during persistency as compared to acute infections. Disrupted synthesis of
unsaturated/cyclopropane fatty acids was the only defect that resulted in rapid Salmonella clearance suggesting that this
pathway might contain suitable targets for antimicrobial chemotherapy of chronic infection.
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Introduction
Persistent pathogens represent a major problem for control of
infectious diseases [1]. Extensive drug tolerance of persisters to all
available antimicrobials often leads to treatment failures and
relapse. Persistent pathogens may adopt a non-replicating
dormant stage with no requirement for macromolecular synthesis
comprising most current antimicrobial targets [2]. As a conse-
quence, such dormant stages are tolerant to most antibiotics. In
addition, low metabolic activity during dormancy might minimize
vulnerability to perturbation. In fact, it remains unclear if dormant
persisters have any essential maintenance requirements for
survival that could provide opportunities for eradication through
antimicrobial chemotherapy.
Various in vitro models have been used as an approximation of
chronic infection with dormant persisters. Data obtained with
these models revealed differential perturbation effects depending
on the particular model and the respective pathogen [3,4,5,6,7,8].
As an example, proton motive force-driven ATP synthesis has
been shown to be essential for Mycobacterium tuberculosis survival in
a hypoxia in vitro model [9]. Indeed, inhibition of ATP synthase
accelerates mycobacterial eradication in patients [10]. On the
other hand, diminishing ATP levels can actually promote E. coli in
vitro persister formation [1]. Additional in vivo models could help
to compare persister maintenance requirements under relevant
conditions. However, except for Mycobacterium tuberculosis, practical
in vivo persistency models are largely lacking.
Salmonella enterica can cause diarrhea or systemic disease called
typhoid/paratyphoid fever. A substantial fraction of systemically
infected individuals develops asymptomatic chronic infection
[11,12]. In many cases, Salmonella persists in biofilms on gallstones
but persisting Salmonella have also been detected in liver [13] and
lymph nodes [14]. Surgical removal of gallstones is required for
successful treatment of Salmonella in gallstones biofilms, while
extended treatment with potent fluoroquinolone antibiotics is
recommended for treatment of chronic Salmonella tissue coloniza-
tion [15].
In genetically resistant mice, Salmonella cause an acute infection
with exponential Salmonella proliferation. However, after Salmonella
peak colonization and partial clearance Salmonella persist at low
levels and this can cause relapses [14]. Genetic screens have
identified some factors that might support chronic Salmonella
survival in this model [12]. However, Salmonella mutants defective
for genes relevant during the initial acute phase would be lost early
on without reaching persistency. This problem could be
circumvented using inducible gene cassettes but this is impractical
for testing many candidate genes.
In this study, we used a simple chronic mouse Salmonella
infection model in which a substantial Salmonella subpopulation
survived without previous exponential proliferation. Interestingly,
Salmonella survived even prolonged treatment with a fluoroquino-
lone antibiotic thus mimicking treatment failures. In this stringent
in vivo model, almost all tested Salmonella activities were dispens-
able confirming extensive resilience of persistent pathogens against
perturbation. On the other hand, the data also revealed a few
novel candidate targets that could be explored for their suitability
to control chronic infections.
Results
Persistency Model using Salmonella purA ssaGH
Wildytpe Salmonella SL1344 grew exponentially in spleen of
infected genetically susceptible BALB/c mice (Figure S1A). To
generate a practical Salmonella persistency model, we constructed
a Salmonella SL1344 derivative that survived but largely failed to
proliferate in systemically infected mice. Specifically, we combined
two mutations that had previously been shown to impair Salmonella
in vivo growth: purA which blocks adenosine biosynthesis [16], and
ssaGH which inactivates the SPI-2 (Salmonella pathogenicity island
2)-associated type three secretion system required for intracellular
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Salmonella growth and virulence [17]. Both purA and SPI-2
mutations have previously been shown to result in long-term
persistence with minimal acute virulence, but our initial charac-
terization revealed some in vivo proliferation of the individual
mutants after i.v. administration (Figure S1B). In contrast, the
double mutant Salmonella purA ssaGH was initially largely cleared
from spleen and liver (Figure S1C) consistent with early killing
during acute salmonellosis [18], but maintained largely constant
bacterial tissue loads thereafter (Fig. 1A, B) suggesting limited net
growth.
To determine the suitability of this model for evaluating
antimicrobial targets during persistency, we treated infected mice
with the antibiotic enrofloxacin. This antibiotic belongs to the
fluoroquinolone class, which is uniquely effective against non-
growing bacteria in vitro [19], and the treatment of choice for
human persistent salmonellosis although effective therapy might
require several weeks of treatment [15]. Enrofloxacin has been
shown to be well absorbed after oral administration, with
penetration into all tissues [20]. Indeed, enrofloxacin is the most
effective drug in the mouse typhoid fever where it diminishes
wildtype Salmonella loads in spleen and liver to levels below the
detection threshold within one to two days of treatment although
relapses occur unless treatment is continued for several days
indicating some residual Salmonella persistence [21,22]. In our
persistency model, the same enrofloxacin treatment initially
diminished spleen loads of Salmonella purA ssaGH, but in contrast
to previous findings for wildtype Salmonella, a substantial surviving
subpopulation of Salmonella purA ssaGH stabilized within two days
and remained clearly detectable during at least four days of
treatment (Fig. 1A). Liver loads continuously decreased during
prolonged treatment suggesting somewhat different Salmonella
physiological states and/or differential pharmacokinetics in the
two host tissues. We determined MIC (minimal inhibitory
concentration) values of the inocculum and ten clones recovered
from spleen and liver of two different mice after four days of
enrofloxacin treatment. All clones were enrofloxacin sensitive with
the same MIC value of 0.06 mg l21 indicating that Salmonella
persisted because of partial tolerance or limited antibiotic
availability, but not emergence of resistant mutants. The sub-
stantially increased persistence of Salmonella purA ssaGH during
enrofloxacin treatment indicated that our model offered a practical
approach to study treatment failures during persistency. Enro-
floxacin efficacy also provided a suitable benchmark for potential
new Salmonella persistency targets.
Salmonella Defects with Minor Persistency Phenotypes
Only a small number of Salmonella genes are absolutely essential
for Salmonella survival and growth in host tissues during acute
salmonellosis [23]. Some of these genes might also be relevant for
Salmonella persistency. To test this hypothesis we transduced 12
mutations into the parental Salmonella purA ssaGH strain, and
determined persistence capabilities of the resulting strains in
competitive infections with mixtures with the parental strain. At
day 7 post infections, most strains had small colonization defects
compared to the parental strain as indicated by competitive indices
that were close to 1. These data suggested that most tested genes
had only minor impact on Salmonella persistency in our model
despite their crucial importance during acute infections (Fig. 2).
As an example, ubiC encoding chorismate lyase is required for
ubiquinone biosynthesis. During acute infection, Salmonella ubiC is
completely cleared from infected mice within one day indicating
absolute essentiality [23]. In striking contrast, Salmonella purA ssaGH
ubiC survived at high levels indicating dispensability of ubiquinone-
mediated oxidative respiration during persistency. Similarly,
functional ATPase is essential for acute Salmonella virulence [24],
but we found it to be fully dispensable during persistency. This was
in striking contrast to various Mycobacterium tuberculosis models that
suggest ATPase to be a particularly attractive target for this
pathogen [9,10]. Another case with strikingly different relevance in
acute [25] vs. persistent Salmonella infections was recA involved in
DNA repair. More expectedly, trxA encoding a thioredoxin
essential for SPI-2 function [26], had no detectable role in
Salmonella purA ssaGH presumably because SPI-2 was already
inactive in this strain.
Polyphosphate biosynthesis or fatty acid degradation were
known to be largely dispensable during acute infection but had
Figure 1. Colonization kinetics of Salmonella enterica serovar Typhimurium purA ssaGH in systemically infected BALB/c mice. Data are
shown for spleen (A) and liver (B) of individual untreated mice (open circles), and mice that were treated from day two post infection with
enrofloxacin (filled circles). Statistical significance of clearance at day 6 compared to day 4 were determined by t-test of log-transformed data (**,
P,0.01; n.s., not significant).
doi:10.1371/journal.pone.0042007.g001
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some role in other chronic Salmonella infection models [27,28].
However, in our stringent model both activities had weak effects
indicating their dispensability for persistency. All these negative
results suggested a severely limited number of suitable targets for
control of persistent Salmonella infections.
Salmonella Defects with Moderate Persistency
Phenotypes
In contrast to all these cases, two mutations, asd and gutQ yrbH,
showed moderate phenotypes in our model (Fig. 3). asd encoding
aspartate semialdehyde dehydrogenase is required for biosynthesis
of the cell-wall peptidoglycan component diaminopimelic acid. A
Salmonella asd strain spontaneously lyses in vitro and is completely
cleared within one day from systemically infected mice [23].
However, Salmonella purA ssaGH asd was only partially cleared
during the first day post infection which might reflect residual
proliferation of some Salmonella and/or difficulties in establishing
a suitable systemic niche [18]. Thereafter, this strain persisted at
slowly declining levels in spleen. This could reflect non-essentiality
of cell-wall synthesis for non-growing bacteria [19]. In contrast,
liver loads rapidly declined suggesting a substantial fraction of
Salmonella purA ssaGH with active cell-wall turnover/growth in
liver. Similarly, Salmonella purA ssaGH gutQ yrbH that required
supplementation with the lipopolysacharide precursor arabinose-
5-phosphate to grow in vitro [29] and was highly attenuated
during acute infections (our unpublished data), maintained high
levels in spleen but was cleared from liver suggesting limited
lipopolysaccharide demands during Salmonella persistency. Both
genes thus were unsuitable as targets.
Two additional mutants had very severe colonization defects
but still maintained stable small loads indicating non-essentiality
for seven day persistence. Salmonella purA ssaGH ribB defective for
3,4-dihydroxy-2-butanone 4-phosphate synthase which is involved
in riboflavin biosynthesis, was cleared within one day post
infection to very low levels in both spleen and liver, but stabilized
thereafter particularly in liver. This might reflect differential
availability of host riboflavin supplementation in these two tissues.
Importantly, these data showed that Salmonella with defective
riboflavin biosynthesis can survive in vivo for extended periods.
Another strain that was rapidly cleared from spleen had a defect in
iscS encoding cysteine desulfurase involved in repair of iron-sulfur
clusters and tRNA modification [30]. This mutant also dropped to
very low loads in liver but still maintained detectable loads at seven
days post infection.
b-ketoacyl-ACP Synthase I Essentiality for Salmonella
Persistency
Finally, there was a single mutant with a more promising
phenotype (Fig. 4A). Salmonella purA ssaGH fabB defective for b-
ketoacyl-ACP synthase I required for biosynthesis of unsaturated
fatty acids and cyclopropane fatty acids, was progressively cleared
from both liver and spleen. During clearance, residual Salmonella
purA ssaGH fabB were recovered from mice mostly as small-colony
variants. Withdrawal of fatty acid supplementation in vitro
similarly enriched small-colony variants of this strain (Fig. 4B),
suggesting that reduced growth and metabolism might enhance
survival of this mutant when external fatty acids are unavailable.
However, even small-colony variants were rapidly cleared from
mouse tissues. Small colony variants usually reflect decreased
growth rate which can be caused by diverse Salmonella defects such
as dimished respiratory activity [31]. Elucidation of the actual
mechanisms that caused our SCV’s was difficult because small-
colony variants of Salmonella fabB generated in vivo or in vitro
quickly reverted to fast growth upon sub-culturing in presence of
oleic acid supplementation.
To test the suitability of this target for antimicrobial chemo-
therapy, we administered thiolactomycin [32], a slow onset
inhibitor of b-ketoacyl-ACP synthase I that is effective in mouse
infection models with extracellular pathogens [33]. However, safe
doses did not diminish Salmonella purA ssaGH loads in spleen (data
not shown). This could reflect the low target affinity of this
inhibitor and/or poor delivery to Salmonella that persist in-
tracellularly in infected macrophages [14,21].
Discussion
Chronic infections represent a major health problem. Eradica-
tion often requires long-term treatment that causes compliance
problems, facilitates resistance development, and often fails to
prevent relapse. Many chronic infections are likely to be caused by
persistent pathogens in a dormant state with minimal cellular and
metabolic activities. In fact, it remains unclear if such dormancy
has any basal maintenance requirements that could be targeted for
therapy. Various in vitro and in vivo models have been established
to determine requirements of persistent pathogens. However,
results depend on the particular model and it remains unclear how
well these models mimic relevant conditions during chronic
infections. It is likely that even within one infected host tissue,
various microenvironments exist that might induce distinct forms
of persistency [34,35].
Here we established a simple Salmonella mouse infection model
in which Salmonella with dual metabolic and virulence defects
persisted at constant tissue loads without an initial acute infection
that hampers functional analysis in a more natural Salmonella
infection in genetically resistant mice [12]. Indeed, in this model
a substantial fraction of such Salmonella reached a non-proliferating
state with minimal cell wall turnover within one day post infection
in spleen, and a substantial Salmonella subpopulation even survived
chronic treatment with a fluoroquinolone. This was surprising
since the same treatment diminishes wildtype Salmonella loads in
spleen to non-detectable levels [21,22], and since fluoroquinolones
are the most potent, but still only partially effective antibiotic to
Figure 2. Competitive indices (CI) of various Salmonellamutants
vs. the parental Salmonella purA ssaGH strain in infected spleen
(open circles) and liver (filled circles). Data are shown for
individual mice at day seven post infection. A competitive index of 1
indicates equal colonization capabilities of mutant and parental strains.
Statistical significance was determined by t-test of log-transformed
data. Spleen colonization of mutants ppk, recA, trxA, ubiC, and fadD fadK
was significantly lower compared to the parental strain (P,0.05). Liver
colonization of mutants ppk, recA, and fadD fadK was significantly lower
compared to the parental strain (P,0.05).
doi:10.1371/journal.pone.0042007.g002
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eradicate persistent salmonellosis [15] and non-growing bacteria in
general [2,19]. These data suggested that our model represented
a stringent test for identifying targets that might be useful in
clinically relevant settings. On the other hand, the emergence of
small-colony variants of a fabB mutant suggested that in this model
persistent Salmonella still had some metabolic activities that could
be diminished to relax residual maintenance requirements.
Salmonella in liver remained sensitive to fluoroquinolone
treatment and required continuous de novo cell wall synthesis.
These data suggested that despite purine auxotrophy and in-
activity of the SPI-2 type III secretion system, liver microenviron-
ments might permit residual Salmonella proliferation in this tissue.
Liver colonization was therefore less suitable as readout for
Salmonella maintenance requirements during persistency. On the
other hand, distinct Salmonella microenvironments in this organ
provided complementary information for target evaluation. As an
example, liver seemed to provide conditions that enable at least
partial survival of Salmonella mutants defective for riboflavin
biosynthesis or repair of iron-sulfur clusters, in contrast to
conditions in spleen. Antimicrobial chemotherapy should eradi-
cate Salmonella from all host organs including liver suggesting that
the corresponding targets might be unsuitable.
The Salmonella metabolic network contains more than 1200
different enzymes that could all represent potential antimicrobial
targets. However, only a very small number of these enzymes are
sufficiently important for Salmonella physiology to qualify as
potentially suitable targets to control acute infections [23].
Interestingly, the data from this study suggested that almost all
of these targets might be unsuitable to treat persistent infections
indicating strikingly different Salmonella requirements for survival
as compared to growth in host tissues. Activities that were
absolutely essential during acute infection, but dispensable during
Figure 3. Colonization kinetics of four compromised mutants in spleen (open circles) and liver (filled circles). Small residual
colonization levels after seven days of infection suggested that all shown genes contributed to Salmonella survival but were not absolutely essential.
Statistical significance of clearance at day 7 compared to day 1 in spleen was determined by t-test of log-transformed data (***, P,0.001).
doi:10.1371/journal.pone.0042007.g003
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persistency, include cell wall synthesis, ubiquinone-dependent
aerobic respiration, proton motive force-dependent ATP synthesis,
translational accuracy, DNA repair, and thioredoxin-mediated
redox balance. Dispensability of PMF-driven ATP synthesis
highlighted the stringency of our model but might also reflect
differences between Salmonella and other pathogens. In addition,
activities that play important roles in other persistency models
including fatty acid degradation and polyphosphate storage were
also dispensable in our model. These data indicate that Salmonella
purA ssaGH had limited requirements for extended in vivo survival.
We found only a single defect, inactive biosynthesis of
unsaturated fatty acids and cyclopropane fatty acids that resulted
in clearance to non-detectable tissue loads within a few days.
Interestingly, clearance kinetics for defective mutants were faster
compared to the best current antimicrobial drug enrofloxacin for
chronic salmonellosis suggesting that the corresponding targets
could potentially help to improve treatment of such disease. It is
possible that defective fatty acid biosynthesis could result in
accumulation of toxic intermediates although such toxic inter-
mediates have not yet been described in the respective pathway
and the mutant grows normally in vitro if supplemented with oleic
acid. Flux-Balance Analysis [36] of a genome-scale metabolic
model [37] predicted additional expected essential genes in the
fatty acid biosynthesis pathway (accA, accB, accC, accD, acpP, fabA,
fabD, fabG, fabI) but no other pathways reflecting redundancy in
providing required precursors such as malonyl-CoA, NADPH,
and NADH.
Unsaturated fatty acids and their derivatives cyclopropane fatty
acids together comprise about one-half the Salmonella fatty acid
content [38]. Essentiality of de novo synthesis could suggest
continuous internal turnover, damage, and or loss to the
environment. Damage/loss of membranes has previously been
proposed as a potential strategy to control persisters [39]. Reactive
oxygen species can readily damage mammalian polyunsaturated
fatty acids, but bacterial unsaturated fatty acids that usually
contain only a single double bond are refractory to oxidative
damage [40]. Alternatively, membranes could also be lost by
shedding outer membrane vesicles [41]. On the other hand,
continuous synthesis of another outer membrane component,
lipopolysaccharide may not be needed for Salmonella persistence
based on the slow clearance of Salmonella purA ssaGH gutQ yrbH
from infected spleen (Fig. 3). Further studies are needed to clarify
the function of de novo fatty acid synthesis and the impact of the
host immune response on fatty acid requirements during Salmonella
persistency. It is also important to note that host fatty acids (both
saturated and unsaturated) might be sufficiently available in other
infectious disease models, especially in case of extracellular
pathogens [42].
In conclusion, we established a practical, highly stringent in vivo
persistency model. Data obtained with this model revealed that
key metabolic activities that are essential during acute salmonel-
losis might be dispensable during persistent Salmonella infections.
On the other hand, at least some Salmonella metabolic activities
might be crucial for persistency and the model could help to
identify additional requirements in subsequent studies.
Materials and Methods
Bacterial Genetics
We used strain Salmonella enterica serovar typhimurium SL1344
hisG xyl [43] as parental wild type strain. Salmonella mutants were
constructed by lamda red- recombinase mediated allelic re-
placement [44] followed by general transduction using phage
P22 int [45]. Resistance cassettes were flanked with FRT sites for
removal using FLP recombinase [44]. All strains were cultivated at
37uC in Lennox LB medium containing 90 mg/ml streptomycin
and 50 mg/ml kanamycin, 20 mg/ml chloramphenicol, and/or
100 mg/ml ampicillin, as appropriate. Auxotrophs were supple-
mented with 40 mg/ml riboflavin (ribB), 0.1% oleate (fabB), 50 mg/
ml diamino pimelic acid (asd), 15 mM D-arabinose-5-phosphate/
Figure 4. Clearance of Salmonella purA ssaGH fabB from infected mice. A) Colonization kinetics in spleen (open circles) and liver (filled circles).
Similar results were obtained in three independent experiments. Statistical significance of clearance at day 7 compared to day 1 were determined by
t-test of log-transformed data (***, P,0.001; **, P,0.01; *, P,0.05; n.s., not significant). B) Heterogeneity of colony size on agar plates. Similar data
were obtained for two independent in vitro cultures and five independent ex vivo cultures.
doi:10.1371/journal.pone.0042007.g004
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10 mM glucose-6-phosphate (gutQ yrbH). Agar plates containing
oleate were always freshly prepared and maintained at 37uC to
keep oleate homogeneously dispersed. Minimal inhibitory con-
centrations (MIC) for enrofloxacin were determined as described
[46].
Mouse Infections
All animals were handled in strict accordance with good animal
practice and all animal work was approved by local animal care
and use committee (license 2239, Kantonales Veterina¨ramt BS).
Eight to 12 weeks old female BALB/c mice were infected
intravenously with 106 CFU Salmonella from late exponential LB
cultures. For some experiments, we administered enrofloxacin
(2 mg/ml) in the drinking water beginning two days post infection
[21], or thiolactomycin (two doses of 2 mg per mouse). For
competitive infections, mutant Salmonella carrying different antibi-
otic resistance cassettes were mixed before administration. The
actual bacterial dose was confirmed by plating. At various time
intervals post infection, mice were sacrificed, spleen and liver
collected aseptically in 1 ml of 0.1% Triton Tx-100, and number
of viable bacteria per organ was determined by plating tissue
homogenates on appropriate selective media. Competitive indices
(CI = output ratio/input ratio) were calculated based on plate
counts for inoculum and tissue homogenates collected at seven
days post infection.
In Silico Modeling
To predict additional targets, we used a genome-scale
computational Salmonella in vivo metabolism model STMv1.1, an
updated version of the consensus genome-scale metabolism
reconstruction STMv1 [37] (manuscript in preparation). We used
production of unsaturated fatty acids as objective function and
determined all genes that were predicted to be essential for this
function with Flux-Balance Analysis [36] using MatLab and the
COBRA toolbox [47].
Supporting Information
Figure S1 Colonization kinetics of various Salmonella
mutants in spleen (open circles) and liver (closed circles)
of systemically infected BABL/c mice. A) Colonization of
wildtype Salmonella SL1344 after systemic infection with 350 CFU.
B) Colonization of SL1344 purA after infection with 1.856106
CFU and SL1344 ssaGH after infection with 1.26106 CFU. C)
Initial colonization of SL1344 purA ssaGH after infection with
8.56105 CFU. Statistical significance of colonization level
differences at day 2 and 4 (for data in A), clearance at day 7
compared to day 1 (for data in B), or colonization levels at 24 h
compared to 2 h (for data in C) were determined by t-test of log-
transformed data (***, P,0.001; **, P,0.01; *, P,0.05).
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2.1.3 Additional Results 
Supplementary Figure 1 (Fig S1) 
Colonization kinetics of various Salmonella mutants in spleen (open circles) and 
liver (closed circles) of systemically infected BABL/c mice.
A) Colonization of wildtype Salmonella SL1344 after systemic infection with 350
CFU. B) Colonization of SL1344 purA after infection with 1.85×106 CFU and
SL1344 ssaGH after infection with 1.2×106 CFU. C) Initial colonization of SL1344
purA ssaGH after infection with 8.5×105 CFU. Statistical significance of colonization
level differences at day 2 and 4 (for data in A), clearance at day 7 compared to day 1 
(for data in B), or colonization levels at 24 h compared to 2 h (for data in C) were 
determined by t-test of log-transformed data (***, P<0.001; **, P<0.01; *, P<0.05). 
Figure S1 
Results 
Part B – Immunity to intracellular Salmonella
depends on surface associated antigens
Results-Part B-Publication II 
42
2.2 Immunity to intracellular Salmonella depends on surface 
 associated antigens.
PLoS pathogens, 2012, 8(10), e1002966.
Somedutta Barat†, Yvonne Willer†, Konstantin Rizos†, Beatrice Claudi, Alain
Maze´,Anne K. Schemmer, Dennis Kirchhoff, Alexander Schmidt, Neil Burton, Dirk 
Bumann.
†equal contribution
2.2.1 Abstract 
Enteric fever causes tremendous morbidity and moratality worldwide. Current control 
strategies are becoming inefficient because of the increasing antibiotic resistance, and 
emergence of new Salmonella serovars that are not covered by the currently licensed 
vaccines. Hence, there is an urgent need for novel Salmonella vaccine with broad 
serovar coverage. In this study we did experiments to determine the relevant antigen 
properties in a mouse Salmonella typhoid fever model that might be relevant for 
developing a new Salmonella vaccine. Our data revealed novel protective Salmonella
antigens that conferred partial protection against virulent Salmonella. Moreover, we 
also found that the protective antigens were all surface associated suggesting a crucial 
role of antigen localization. Results from model antigens expressed in Salmonella
suggested that surface localization might enhance antigen immunogenicity. However, 
data from protective surface autologous Salmonella antigens did not induce superior 
immune responses during infection compared to the internal antigens. We also 
observed that live Salmonella segregated away from dead Salmonella that released 
internal antigens. Detection and destruction of live Salmonella possibly required 
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recognition of surface exposed antigens. In conclusion, these data suggested 
prioritization of Salmonella antigen candidates based on surface association. 
Statement of my work
I contributed to this work by generating sixteen Salmonella outer membrane  
associated antigens, and one inner membrane antigens, and tested their protectivity in 
mouse typhoid fever model with immunization/challenge experiments. I also 
predicted the T cell epitopes of all the  thirty seven Salmonella antigens using 
bioinformatic tools, and  contributed in the strucutural modeling for  the selected 
Salmonella antigens. 
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Abstract
Invasive Salmonella infection is an important health problem that is worsening because of rising antimicrobial resistance
and changing Salmonella serovar spectrum. Novel vaccines with broad serovar coverage are needed, but suitable protective
antigens remain largely unknown. Here, we tested 37 broadly conserved Salmonella antigens in a mouse typhoid fever
model, and identified antigen candidates that conferred partial protection against lethal disease. Antigen properties such as
high in vivo abundance or immunodominance in convalescent individuals were not required for protectivity, but all
promising antigen candidates were associated with the Salmonella surface. Surprisingly, this was not due to superior
immunogenicity of surface antigens compared to internal antigens as had been suggested by previous studies and novel
findings for CD4 T cell responses to model antigens. Confocal microscopy of infected tissues revealed that many live
Salmonella resided alone in infected host macrophages with no damaged Salmonella releasing internal antigens in their
vicinity. In the absence of accessible internal antigens, detection of these infected cells might require CD4 T cell recognition
of Salmonella surface-associated antigens that could be processed and presented even from intact Salmonella. In
conclusion, our findings might pave the way for development of an efficacious Salmonella vaccine with broad serovar
coverage, and suggest a similar crucial role of surface antigens for immunity to both extracellular and intracellular
pathogens.
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Introduction
Enteric fever caused by systemic Salmonella infection causes
tremendous morbidity and mortality worldwide [1]. Current
control strategies become increasingly inefficient as a result of
increasing antimicrobial resistance [2,3] and emergence of
Salmonella serovars that are not covered by currently available safe
vaccines [4,5]. This situation generates an urgent medical need for
novel Salmonella vaccines with broad serovar coverage.
Early killed whole-cell vaccines containing mixtures of different
serovars provide broad protection, but cause unacceptable adverse
reactions [1]. As an alternative to whole-cell vaccines, subunit
vaccines containing a few defined Salmonella components could
minimize adverse reactions. Indeed, vaccines containing the
capsular polysaccharide Vi antigen provide moderate protection
and excellent safety [1]. On the other hand, serovars Paratyphi A
and non-typhoidal Salmonella (NTS) that cause an increasing
number of invasive salmonelloses [6], lack the Vi antigen and are
therefore not covered by Vi vaccines [5]. Apart from Vi, few
Salmonella antigens have been identified, and all of these provide at
best moderate levels of protection against challenge infection with
virulent Salmonella strains in the commonly used mouse typhoid
fever model. Moreover, antigens such as flagellin [7] and OmpD
[8] are poorly conserved among relevant serovars.
For extracellular pathogens with antibody-mediated immunity,
protective antigens must be surface-exposed [9], and this enables
an effective strategy for priorization of antigen candidates [9].
Humoral response to surface antigens can also contribute to
immunity to intracellular pathogens such as invasive Salmonella
[10]. Indeed, Vi which induces protective antibody responses in
human vaccinees, forms an extracellular capsule around Salmonella
Typhi [11]. Two additional antigens that confer partial immunity
in the mouse typhoid fever model, flagellin [7] and SseB [12], are
also part of Salmonella surface structures (flagella, translocon
complex of a type III secretion system). Furthermore, outer
membrane preparations (but not the outer membrane component
lipopolysaccharide) have been suggested to mediate protective
humoral immune responses against extracellular Salmonella bac-
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teremia [13] and attenuated Salmonella strains in the mouse model
[8,14]. A number of porins such as OmpC, OmpD, and OmpF
are highly abundant in such outer membrane preparations
suggesting that they might represent the actual protective antigens
[8,14,15].
However, immunity to Salmonella critically depends also on CD4
T cells [10]. Unfortunately, protective T cell antigens seem to be
rare, and priorization of candidates is difficult since relevant
antigen properties for CD4 T cell responses remain unclear
[9,16,17]. One key precondition for protective responses is
expression of the respective Salmonella antigen during infection
[18], and some data suggest that highly abundant antigens might
be particularly well recognized by CD4 T cells [12,19]. Antigen in
vivo expression can be deduced from various complementary
approaches including screening of promoter trap libraries [20,21],
proteomics [22], serum antibody response [23–26], as well as
mutant virulence phenotypes.
In addition to antigen expression, antigen immunogenicity
could play a major role. Antigen detection by cognate CD4 T cells
requires antigen processing and presentation of the resulting small
peptides by major histocompatibility (MHC) class II molecules.
Peptide sequence properties that are characteristic for well
recognized epitopes, can be used for genome-wide prediction of
promising antigens [27]. However, a large number of non-
protective antigens contain putative high-score epitopes [16,18,28]
which could compromise the discriminatory power of this
approach.
Experimental detection of immune responses to an antigen in
convalescent individuals that have survived infection, demon-
strates that this antigen was expressed in vivo and could be
recognized by the immune system [23–25]. Indeed, this approach
has been recently shown to facilitate identification of protective
Chlamydia antigens [29]. On the other hand, many immunodomi-
nant antigens in convalescent individuals lack protective efficacy,
while a number of protective antigens may induce immune
responses below the detection threshold during natural infection
[17].
Another antigen property that can affect CD4 T cell responses
is antigen localization. In particular, secreted or surface-associated
antigens might induce particularly strong cellular immune
responses because of superior processing, kinetic advantages
compared to internal antigens, and/or physical association with
pathogen-associated molecular patterns (PAMP) such as lipopoly-
saccharide that provide potent stimuli for innate and adaptive
immunity [14,30–36]. Indeed, secretion/surface localization has
been widely used to prioritize candidates for antigen identification.
However, antigens with likely internal localization can also induce
specific CD4 T cell responses that mediate protection against
various intracellular pathogens [37,38].
Taken together, relevant antigen properties for CD4 T cell
mediated immunity to intracellular pathogens remain poorly
characterized, and this impairs antigen priorization for vaccine
development. To address this issue, we compared here 37 diverse
Salmonella antigens in a mouse model that closely mimics human
typhoid fever [39]. The results suggested that recognition of
surface-associated antigens might be necessary to detect and
combat live intracellular Salmonella, whereas recognition of internal
antigens would mediate futile non-protective attack of already
dead Salmonella. In conclusion, we propose a similar crucial role of
surface-associated antigens for immunity to both extracellular and
intracellular pathogens.
Results
Immune responses to Salmonella antigens in
convalescent individuals
To determine immune responses to Salmonella antigens, we
selected 21 broadly conserved Salmonella proteins. We selected
several subunits of the SPI-2 type III secretion system since the
putative translocon subunit SseB of this system showed promising
protectivity in previous studies [12,26]. We also included several
porins since a previous study had shown that OmpD conferred
protection against an attenuated Salmonella mutant [8]. To explore
the role of antigen localization we selected additional proteins
localized in Salmonella cytosol, inner membrane, periplasm, and
outer membrane/surface. To explore the role of antigen
abundance, we determined absolute quantities of more than
1100 Salmonella in infected mouse spleen. Specifically, we purified
Salmonella from infected mouse spleen using flow cytometry as
described [22]. We determined absolute protein quantities in these
ex vivo purified Salmonella using shot-gun proteomics with 30
isotope labeled reference peptides and the iBAQ quantification
method [40] (for detailed description see Materials and Methods
section). From these data, we selected additional antigens with a
large range of abundances (Tab. 1).
To determine potential cross-protection between different
serovars, we cloned the corresponding genes from Salmonella
enterica serovar Typhi (except for OmpD which was obtained from
serovar Typhimurium since it is absent in serovar Typhi). We
expressed the proteins as C-terminal His6-fusions in E. coli
followed by Ni-affinity chromatography purification. We purified
the control antigen GFP-His6 using the same protocol.
We determined immune responses to these antigens in
genetically resistant, convalescent mice that had survived infection
with virulent Salmonella enterica serovar Typhimurium. We detected
antigen-specific CD4 T cells in spleen using a sensitive CD154
assay [41] and measured serum IgG antibody responses using
ELISA. All tested antigens were recognized by CD4 T cells
(Fig. 1A; Tab. 1), many of which secreted IFNc or IL-17 upon
stimulation. Both cytokines play crucial roles in immunity to
Salmonella [10]. Frequencies of responsive CD4 T cells were in the
same range as for flagellin, which has been considered an
immunodominant antigen [42]. These data suggested that
Salmonella infection elicited a broad cellular immune response
Author Summary
Salmonella infections cause extensive morbidity and
mortality worldwide. A vaccine that prevents systemic
Salmonella infections is urgently needed but suitable
antigens remain largely unknown. In this study we
identified several antigen candidates that mediated
protective immunity to Salmonella in a mouse typhoid
fever model. Interestingly, all these antigens were associ-
ated with the Salmonella surface. This suggested that
similar antigen properties might be relevant for CD4 T cell
dependent immunity to intracellular pathogens like
Salmonella, as for antibody-dependent immunity to
extracellular pathogens. Detailed analysis revealed that
Salmonella surface antigens were not generally more
immunogenic compared to internal antigens. However,
internal antigens were inaccessible for CD4 T cell recog-
nition of a substantial number of infected host cells that
contained exclusively live intact Salmonella. Together,
these results might pave the way for development of an
efficacious Salmonella vaccine, and provide a basis to
facilitate antigen identification for Salmonella and possibly
other intracellular pathogens.
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against a large number of in vivo expressed antigens from all
Salmonella compartments in agreement with data observed for S.
Typhi infected human patients [43]. There was no correlation
between in vivo antigen abundance as determined by proteome
analysis of ex vivo purified Salmonella, and CD4 T cell frequency or
cytokine profile (Tab. 1).
Serum antibody responses revealed similar broad recognition of
antigens from several Salmonella compartments (Fig. 1B) in
agreement with previous data for human typhoid fever patients
[24–26,44]. Interestingly, the three immunodominant humoral
antigens T2461, PhoN, and PcgL were all highly expressed in vivo
(Tab. 1) suggesting a potential impact of antigen dose on antibody
responses to Salmonella, although responses to minor antigens did
not correlate with antigen abundance. PhoN has been previously
recognized as an immunodominant antigen [26].
Immunization and challenge infection
Many of the tested Salmonella antigens were capable to induce
cellular and humoral immune responses. To test if these responses
could confer protective immunity, we tested the 21 recombinant
Salmonella antigens in immunization/challenge infection experi-
ments in genetically susceptible BALB/c mice. Based on the
results, we selected 16 additional Salmonella antigens primarily from
the outer membrane, and tested them using the same experimental
immunization/challenge approach (however, we did not measure
their immunogenicity in convalescent mice). For simplicity, we
discuss results for both antigen sets together. Out of 37 tested
antigens, only few antigens enabled prolonged survival after oral
challenge infection with virulent Salmonella compared to control
immunization with the unrelated antigen GFP (Fig. 2; Tab. 1;
poor survival of PhoN-vaccinated animals confirmed recently
published data [26]). In fact, only two antigens (T0937 and T2672)
mediated protective immune responses with P-values below 0.05
in our small experimental groups of only five mice per antigen.
Replicate experiments with larger group sizes might yield
statistical significant results for additional candidates such as SseB
that has already been shown to be protective in two independent
previous studies. Such experiments will be required to select
individual antigens for vaccine development in future studies. On
the other hand, the primary focus of this study was to identify
antigen properties that correlate with protectivity. For this
purpose, the somewhat noisy survival times detected with small
animal groups were still helpful.
As an example, survival times did not correlate with CD4 T cell
responses (Fig. 3A) or serum antibody levels (Fig. 3B) during
natural infection of resistant mice. This could partially reflect
differences in MHC class II haplotypes (H2d in BALB/c vs. H2b in
129/Sv), courses of infection, and potential differences in Salmonella
biology in susceptible vs. resistant mice. However, a recent large-
scale study reports comprehensive immunogenicity data for
BALB/c mice and other mouse strains that had been immunized
with attenuated Salmonella, as well as for human patients [26].
Several antigens that prolonged survival of immunized BALB/c
mice after Salmonella challenge infection in our experiments, elicit
detectable antibody responses in various mouse strains including
BALB/c. However, none of these antigens was found to be
immunodominant [26] and antibodies to antigens IroN and CirA
with the longest survival times were not detected in this and
previous studies. This could reflect differential antigen expression
in virulent vs. attenuated Salmonella, different routes of adminis-
tration, and/or differential expression at various stages of disease
progression. Together, these data provide no evidence for
immunodominance in convalescent or immune individuals as a
prerequisite for protectivity.
Figure 1. Cellular and humoral immune responses of convalescent Salmonella-infected mice to recombinant Salmonella antigens. A)
Antigen-specific CD4 T cell frequencies as detected by CD154 upregulation (red) and IFNc (green) or IL-17 (blue) secretion. The data represent means
6 SE of three mice. Responses to Salmonella antigens in non-infected control mice were subtracted (see also Fig. S1). B) Serum antibody responses to
Salmonella antigens. The data represent means 6 SE of 11 convalescent mice (filled circles) and means 6 SE for ten non-infected control mice (open
circles).
doi:10.1371/journal.ppat.1002966.g001
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Interestingly, in vivo expression levels also did not correlate with
survival times (Fig. 4A). In fact, the two antigens that enabled the
longest survival, IroN and CirA, had in vivo expression levels that
were below our detection threshold. By comparison, antigens
T2461 and PhoN were highly expressed in vivo and induced
potent CD4 T cell and humoral responses in convalescent
individuals, yet failed to prolong survival (in agreement with
previous observations [26]).
In contrast to immunogenicity and in vivo abundance, antigen
localization seemed to be crucial (Fig. 4B). In fact, antigens
enabling prolonged survival times were exclusively associated with
the Salmonella surface, either as experimentally validated outer
membrane-associated lipoproteins [45], as outer membrane
proteins, or as the translocon complex of the type III secretion
system encoded by Salmonella pathogenicity island two (SPI-2)
(Tab. 1). These data suggested distinct immune responses to
Salmonella outer membrane/surface antigens that fundamentally
differ from those to internal antigens.
On the other hand, surface localization alone was not sufficient
for protectivity. As examples, membrane proteins PgtE, PagC, and
Tsx were highly expressed in vivo and PgtE and PagC elicited
potent CD4 T cell responses in convalescent individuals (Fig. 1A).
PagC is also well recognized by antibodies and CD4 T cells of
human typhoid fever patients [24]. However, PagC, PgtE, and
Tsx failed to prolong survival. Interestingly, structural models
revealed that these proteins were largely buried in the outer
membrane bilayer (Fig. 5), and their extracellular loops contained
at most one predicted CD4 T cell epitope each, and only up to two
linear antibody epitopes, respectively. Importantly, key amino
acids in exposed T cell epitopes differed among Salmonella serovars
which might have impaired cross-protectivity of serovar Typhi
antigens against serovar Typhimurium challenge infection. Similar
observations were also made for non-protective TolC, OmpC,
OmpD, and OmpF. By contrast, antigens IroN, CirA, and FepA
that enabled extended survival after challenge infection, had
extracellular loops with several highly conserved T and B cell
epitopes (Fig. 5). Further studies with larger data sets will be
required to validate the relevance of these structural properties for
protectivity.
Impact of Salmonella antigen localization in an
ovalbumin model
The strong bias for surface-associated Salmonella antigens might
have been expected based on previous data for model antigens
suggesting superior immunogenicity of surface antigens compared
to internal antigens [30,46–50]. However, these model antigen
Figure 2. Survival curves of mouse groups immunized with 37 different Salmonella antigens (thin lines) or the control antigen GFP
(thick dashed line). For better visualization, curves were slightly shifted. The longest survival was observed for antigens IroN and CirA. For statistical
analysis by log-rank test see Table 1.
doi:10.1371/journal.ppat.1002966.g002
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Figure 3. Comparison of Salmonella antigen protectivity against primary infection and immunogenicity in convalescent resistant
mice. A) Relationship between antigen protectivity against primary infection and cognate CD4 T cell responses in convalescent mice (same data as
Fig. 1A). Protectivity is expressed as ‘‘survival time extension’’, which is the difference in median survival time of a group of five immunized mice
compared to a control group of five mice that were immunized with GFP. B) Relationship between antigen protectivity and serum antibody
responses in convalescent mice (same data as Fig. 1B).
doi:10.1371/journal.ppat.1002966.g003
Figure 4. Salmonella antigen protectivity does not correlate with in vivo antigen abundance but depends on antigen localization
within the Salmonella cell. A) Relationship between antigen protectivity and in vivo abundance as determined by quantitative proteome analysis
of ex vivo purified Salmonella (means6 SD for three independently infected mice; b.d., below detection threshold). B) Relationship between antigen
protectivity and antigen localization within Salmonella (C, cytosol; IM, inner membrane; P, periplasm; LP, outer-membrane associated lipoprotein;
OMP, outer membrane protein; S, surface). Statistical significance of differences between internal and outer membrane/surface antigens was tested
using the non-parametric Mann-Whitney U test.
doi:10.1371/journal.ppat.1002966.g004
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Figure 5. Structural models and exposed immune epitopes of various Salmonella outer membrane proteins. The outer membrane is
shown as a grey area, predicted CD4 T cell epitopes in exposed loops are shown in red, potential antibody binding sites are shown in blue, and
overlapping T and B cell epitopes are shown in magenta. Partially exposed epitopes are shown in pale colors. Amino acid residues that differ between
Salmonella enterica serovars Typhimurium and Typhi are shown in green. For TolC only the outer membrane-associated part is shown. LPS structures
as observed in FhuA-LPS crystals [93] are also shown.
doi:10.1371/journal.ppat.1002966.g005
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data were in striking contrast to results from us and others
demonstrating comparable immune responses to autologous
Salmonella antigens from all Salmonella compartments (Fig. 1A,B).
Furthermore, there was no obvious correlation between immuno-
genicity and survival times (Fig. 3A,B).
To better understand these discrepancies between model
antigens and autologous Salmonella antigens, we re-visited the
impact of antigen localization using a well-characterized, sensitive
model system in which a MHC II-restricted T cell epitope from
ovalbumin comprising amino acids 319 to 343 (OVA) is
recognized by adoptively transferred cognate T cell receptor
transgenic CD4 T cells [51,52]. We targeted the OVA epitope to
different Salmonella compartments by fusing it to various proteins
with known localization: GFP_OVA (cytosol [53]), OVA_MglB
(periplasm [54]), Lpp_OVA (inner leaflet of the outer membrane
[55]), and OVA_AIDA (outer leaflet of the outer membrane [56])
(Fig. 6A). To modulate expression levels, we used ribosome
binding sites with differential translation initiation efficiency [12].
We expressed these fusion proteins from an in vivo inducible
promoter [57] in an attenuated Salmonella enterica serovar
Typhimurium aroA strain [58]. Antigen expression and localization
was validated in in vitro cultures using cell fractionation followed
Figure 6. CD4 T cell responses to Salmonella expressing an ovalbumin model antigen in various compartments. A) Schematic overview
of fusion proteins that target an immunodominant ovalbumin epitope (OVA) to various Salmonella cell compartments. B) Flow cytometric analysis of
ovalbumin-specific CD4 T cell activation in a T cell receptor-transgenic adoptive transfer model. Mice were infected with control Salmonella
expressing GFP (left) or Salmonella expressing LPP_OVA (right). Ovalbumin-specific transgenic CD4 T cells were detected with a clonotypic
monoclonal antibody and analyzed for forward scatter and expression of the very early activation marker CD69. The dashed line was used to count
CD4 T cell blasts. Similar observations were made for more than hundred mice in several independent experiments. C) Relationship between
Salmonella Peyer’s patches colonization and OVA-specific CD4 T cell induction in mice infected with Salmonella expressing high levels of LPP_OVA
(filled circles) or low levels of GFP_OVA (open circles). Data represent means 6 SEM’s for groups of five to six animals from three independent
experiments. CD4 T cell blasts correlated with Salmonella Peyer’s patches colonization for both strains (Spearman test, P,0.05 in both cases). The
slopes of the two curves differed (ANCOVA; P,0.05). D) OVA-specific CD4 T cell induction in mice infected with Salmonella expressing OVA at various
levels (open circles, low abundance; filled circles, high abundance) in four different compartments. The dashed line represents CD4 T cell responses to
saturating levels of cytosolic OVA. The star represents data for Salmonella expressing moderate levels of cytosolic OVA together with cholera toxin B
and AIDA. Data represent means 6 SEM’s for groups of ten to twenty mice. Statistical significance of differences to Salmonella expressing saturating
levels of cytosolic OVA were tested using Mann-Whitney U test (*, P,0.05; **, P,0.01).
doi:10.1371/journal.ppat.1002966.g006
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by western blotting, trypsin treatment, and antibody binding (Fig. S2).
Interestingly, small fractions of both outer membrane antigens
LPP_OVA and partially processed OVA_AIDA were released to the
extracellular surroundings when expressed at high levels (Fig. S2C) in
agreement with previous findings for similar proteins [59–61].
We infected BALB/c mice with Salmonella strains by intragastric
gavage of 1010 CFU. All Salmonella strains colonized intestinal
Peyer’s patches with peak tissue loads of 36104 to 1.56105 CFU
at day seven post infection as observed before for attenuated
Salmonella aroA [62]. All constructs stably maintained their
respective ovalbumin-expression plasmids (.80% at 7 days post
infection). To determine antigen-specific CD4 T cell induction, we
adoptively transferred OVA-specific TCR-transgenic CD4 T cells
one day prior to Salmonella infection. OVA-specific T cells
upregulated the early activation marker CD69 and formed blasts
in mice infected with Salmonella expressing ovalbumin model
antigens, but not in mice infected with control Salmonella (Fig. 6B)
as observed previously [53]. CD4 T cell induction kinetics were
similar for all constructs and consistent with our previous
observations [53] suggesting a response to Salmonella in situ
antigen expression, but not to the inoculum [57,63].
To compare T cell responses against the various Salmonella
constructs, we measured T cell blast formation at peak Salmonella
colonization at day seven post infection. Salmonella tissue loads
varied somewhat between individual mice but for each construct,
there was a linear relationship between the number of ovalbumin-
specific DO11.10 blasts and Salmonella loads (Fig. 6C) in agreement
with our earlier observations [57]. To determine the specific
immunogenicity of each Salmonella strain, we calculated the
average ratio of DO11.10 CD4 T cell blasts per viable Salmonella
(i.e., the slopes in Fig. 6C) [57]. The data revealed comparable
immunogenicity of model antigens GFP_OVA and OVA_MglB
(Fig. 6D). In contrast, high-level expression of surface-associated
LPP_OVA and OVA_AIDA induced superior responses that
clearly surpassed responses even to saturating amounts [12] of
internal GFP_OVA.
The OVA_AIDA fusion protein contained a fragment of the
virulence factor AIDA from enteropathogenic E. coli and a cystein-
deficient variant of the cholera toxin B subunit from Vibrio cholerae
[64]. Both components might have stimulatory effects [65,66] that
could potentiate ovalbumin immunogenicity. To test this poten-
tially confounding factor, we compared Salmonella expressing a
suboptimal level of cytosolic GFP_OVA [12] (some 54.000 copies
per Salmonella cell) to Salmonella expressing the same amount of
GFP_OVA together with AIDA and cholera toxin B. Both strains
induced DO11.10 T cell blasts with similar efficacy (Fig. 6D)
Figure 7. Detection of intact and damaged Salmonella cells in infected mouse tissues. A) Flow cytometry of a spleen homogenate infected
with Salmonella sifB::gfp using 488 nm excitation. Gate 1 contains GFP-positive Salmonella. The inset shows the relationship between flow cytometry
data and plate counts for individual mice, the dashed line represents a 1:1 ratio. B) Confocal micrographs of liver cryosections infected with
Salmonella sifB::gfp that were stained with antibodies to Salmonella lipopolysaccharide (red) and macrophage marker CD68 (blue). Individual color
channels are shown with inverted grey scale for better visualization of weak staining. Micrographs represent typical observations for four
independently infected mice. C) Confocal micrographs of lipopolysaccharide-positive particles that lack detectable GFP (even when contrast was
increased compared to B). Such particles were absent in non-infected control sections.
doi:10.1371/journal.ppat.1002966.g007
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suggesting that AIDA and cholera toxin B expression had no
impact on the immunogenicity of Salmonella-encoded OVA.
Taken together, these findings suggested that antigens from all
Salmonella compartments could induce specific CD4 T cell
responses, but highly expressed outer membrane-associated
antigens were clearly superior in agreement with previous
observations in other model systems. However, these data were
in striking contrast to responses to autologous Salmonella antigens
(see discussion).
Distribution of intact and damaged Salmonella in
infected tissues
The fundamentally superior protectivity of surface-associated
Salmonella antigens might reflect their unique accessibility to
antigen processing and presentation in infected host cells in
contrast to internal Salmonella antigens that are shielded by the
Salmonella envelope, and thus remain invisible for the host immune
system until Salmonella is damaged and the bacterial cell breaks
open. To detect intact and damaged Salmonella in infected tissues,
we used cytosolic GFP as a marker for internal antigens.
Salmonella expressing GFP from the chromosomal in vivo
induced locus sifB were readily detected in infected tissue
homogenates using flow cytometry [12] (Fig. 7A). Flow cytometric
counts for GFP+ Salmonella closely correlated with viable counts as
determined by plating (Fig. 7A, inset) suggesting that detectable
GFP levels were present in all live Salmonella.
Confocal microscopy of infected spleen and liver sections
revealed many particles that were stained by a polyclonal antibody
to Salmonella lipopolysaccharide, had typical Salmonella size and
morphology, and contained GFP (Fig. 7B) as previously observed
[53] suggesting that these particles represented live intact
Salmonella. In addition, we also detected numerous lipopolysac-
charide-positive particles with distorted shapes that lacked
detectable GFP (Fig. 7C), and likely represented killed and
partially degraded Salmonella. Such particles were absent in non-
infected control sections. Some Salmonella killing during acute
infections had previously been proposed [67–69]. We observed
some infected cells containing both intact and damaged Salmonella,
but a large number of live Salmonella resided alone (or together with
other live Salmonella) in infected cells with no detectable dead
Salmonella. In such infected cells, internal Salmonella antigens were
thus shielded and inaccessible for immune recognition.
Discussion
There is an urgent medical need for an efficacious Salmonella
vaccine with broad coverage of invasive serovars. One important
bottleneck in the development of such a vaccine is the
identification of suitable protective antigens. In this study, we
identified broadly conserved S. Typhi antigen candidates that
prolonged survival after S. Typhimurium challenge infection in the
mouse typhoid fever model. The protectivity of some of these
candidates should be confirmed with larger experimental groups
to select the best antigen candidates for vaccine development in
future studies.
Two siderophore receptors (IroN, CirA) enabled the longest
survival (Tab. 1) consistent with previous studies that revealed
siderophore receptors including IroN as promising vaccine
antigens in other models [70–72]. Interestingly, siderophore
receptors are induced by iron starvation and/or activation of the
PhoPQ two component sensory system [73]. IroN and CirA
induction could thus contribute to increased protective efficacy of
membrane preparations from iron-starved Salmonella [74], or live
attenuated Salmonella phoQ24 with constitutive hyperactivation of
the PhoP response regulator [75].
On the other hand, all identified antigens still provided at most
partial protection against challenge infection with virulent
Salmonella suggesting a need for additional antigens. Unfortunately,
protective Salmonella antigens might be rather rare as even among
the 37 tested in vivo expressed antigens that were all highly
immunogenic during infection, only a small minority enabled
prolonged survival. OmpC, OmpD, and OmpF were previously
proposed as potential protective antigens based on data obtained
for enriched Salmonella membrane preparations. However, all three
antigens failed to protect in our model. This could reflect higher
stringency of our model (challenge infection with virulent
Salmonella vs. highly attenuated mutant Salmonella), denatured
three-dimensional structures of our recombinant antigen prepara-
tions vs. native antigens, and/or presence of undetected minor
protective antigens (such as IroN and CirA) besides OmpC,
OmpD, and OmpF in the previously used outer membrane
antigen preparations.
Additional protective Salmonella antigens could be identified by
comprehensive immunization/challenge experiments, but this
would require extensive animal experimentation. Antigen prior-
ization using relevant antigen properties could help to narrow
down the number of antigen candidates to more practical
numbers. Unfortunately, some previously proposed antigen
properties seemed to have limited relevance for protectivity in
our model. This included Salmonella in vivo expression levels,
sequence-based antigenicity predictions, and immunodominance
in convalescent individuals. Poor correlation of antigen immuno-
dominance with protective efficacy has also been observed in
tuberculosis [17]. On the other hand, immune recognition in
convalescent individuals can still provide valuable information
about antigen expression during at least some stage of infection
that might be difficult to obtain otherwise [23,29]. Such data thus
could greatly help to prioritize antigen candidates [26].
In contrast to antigen abundance and immunodominance,
surface-association appeared to be an essential prerequisite.
Surprisingly, some surface-associated proteins that enabled pro-
longed survival also included lipoproteins which were likely to
reside in the inner leaflet of the outer membrane facing the
internal periplasmic space with no exposure to the outside. It is
possible that some lipoproteins might flip across the outer
membrane as observed for other Gram-negative bacteria [76].
Moreover, some lipoprotein fraction is constantly released to the
outside through outer membrane vesicle shedding [59,60].
Several mechanisms could contribute to the striking superiority
of surface-associated antigens. Antibody responses are important
for full protection against virulent Salmonella [10], and protective
antibody responses must be directed against surface antigens [9].
On the other hand, CD4 T cells are even more important for
immunity to Salmonella at least in the mouse typhoid fever model
[10], and it is unclear why CD4 T cells should respond to surface-
associated antigens in a fundamentally different way compared to
the much larger number of internal antigens.
In fact, early cell culture experiments suggested no impact of
Salmonella antigen localization on CD4 T cell recognition of
infected cells [77]. However, in this study a large amount of
antigen was already present in the inoculum, and rapid killing of
the majority of phagocytosed Salmonella [78] would have released
this antigen from all Salmonella compartments. Several subsequent
in vivo studies suggested that surface-associated model antigens
might have intrinsically higher immunogenicity compared to
internal model antigens [30,46–50]. However, the various model
antigen targeting constructs could have differed in antigen in vivo
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expression levels, antigen stability, and epitope processing. Fusion
partners could also have direct immunomodulatory effects. We
therefore re-visited this issue and tried to control some of these
factors. Our results clearly supported the previous finding of
superior immunogenicity of highly expressed surface-associated
model antigens in Salmonella.
In surprising contrast to these data from model antigens,
however, humoral and cellular immune responses in Salmonella-
infected convalescent mice did not show any bias for surface-
associated autologous Salmonella antigens in this as well as in a
recent large-scale study [26]. Broad recognition of antigens from
all pathogens compartments has also been observed in Salmonella
Typhi-infected or Chlamydia-infected human patients
[24,25,29,43,44]. Model antigens and autologous antigens were
also discordant with respect to the impact of antigen abundance.
Specifically, our data for ovalbumin model antigens in this and a
previous study [12], as well as similar findings for Mycobacterium
bovis BCG overexpressing Ag85b [19], suggested that high in vivo
expression levels enhance antigen immunogenicity. However, for
autologous Salmonella antigens in vivo expression levels did not
correlate with protectivity. Striking discrepancies between results
for model antigens vs. autologous antigens have also been
observed in other pathogens [38].
Some of the discrepancies could reflect technical issues. In
particular, strong expression of foreign surface model antigens
might induce subtle alteration in Salmonella in vivo properties such
as increasing outer membrane vesicle shedding or alterations in
protein secretion that could affect antigen presentation and
immune recognition. Furthermore, model antigens might not be
representative of autologous antigens that may have been shaped
by host/pathogen co-evolution selecting for weak immunogenicity.
Regardless of the actual causes of these discrepancies, our data
indicated that in contrast to evidence from model antigens,
protective Salmonella surface-associated antigens were not more
immunogenic compared to internal antigens.
As an alternative explanation, surface-associated antigens might
become more rapidly available for immune recognition compared
to internal antigens that are only released after some pathogen
damage. This could be relevant since early immune responses
might facilitate infection control [32]. In the mouse typhoid fever
model, however, a detectable fraction of Salmonella is rapidly killed
early during infection as observed in this and previous studies
[67,69] similar to events during Mycobacterium infection [79].
Consistent with these observations, CD4 T cell induction kinetics
in the ovalbumin model system were similar for Salmonella strains
with internal or surface-associated OVA-expression.
Instead, we propose an alternative explanation based on the
observation that many live Salmonella resided alone, or together
with other live Salmonella, in infected host cells with no dead
Salmonella releasing their internal antigens. As a consequence,
Figure 8. Schematic model for cellular immunity to Salmonella. Salmonella (yellow) reside in intracellular vacuoles in infected host cells.
Salmonella possesses internal (green) and surface-associated (red) antigens. Left) Live Salmonella shield internal antigens, but some of their surface-
associated antigens are accessible for processing and presentation. As a consequence, T cells specific for Salmonella surface antigens can recognize
these infected cells and initiate antibacterial immune effector mechanisms. In contrast, T cells specific for internal Salmonella antigens fail to detect
host cells that contain exclusively intact Salmonella. Right) Dead Salmonella release internal antigens. As a consequence, both surface-exposed and
internal antigens can be processed, presented, and recognized by cognate T cells. However, this recognition is unproductive for infection control
since it targets Salmonella that are already dead.
doi:10.1371/journal.ppat.1002966.g008
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Salmonella internal antigens remained inaccessible for antigen
processing and presentation in these cells. In contrast, surface-
exposed Salmonella antigens, or antigens released by outer
membrane vesicle shedding, could be accessible for processing
and presentation to cognate CD4 T cells for initiation of protective
anti-Salmonella effector mechanisms (Fig. 8). In comparison, CD4 T
cells recognizing internal Salmonella antigens would have limited
impact on infection control because they miss many cells
containing live Salmonella and instead direct their responses to
host cells containing already dead Salmonella. According to this
model, surface-associated antigens thus differ fundamentally from
internal antigens because they are uniquely accessible in host cells
containing only live Salmonella.
Surface-associated/secreted antigens have been shown to be
crucial for CD8 T cell-dependent immunity to Listeria infection
[31,33]. Our data suggested that such antigens might also be
crucial for CD4 T cell mediated immunity to Salmonella and
potentially other intracellular pathogens. Interestingly, some
internal antigens have been shown to confer partial protection in
infectious diseases caused by intracellular pathogens such as
Leishmania [38] and Mycobacterium [37]. In these infections live and
dead pathogens often co-occur in the same host microenviron-
ments [80,81] suggesting that both internal and surface-associated
antigens might be available for T cell recognition and initiation of
antimicrobial immune effector mechanisms targeting both live and
already dead pathogens [82]. We speculate that full protection
might still require immune detection of all live pathogens including
those that reside in microenvironments with yet no accessible
internal antigens from dead pathogens. Further studies are
required to test this hypothesis.
Conclusion
This study suggested novel Salmonella antigens that conferred
partial protection against virulent Salmonella in a stringent typhoid
fever model. High sequence conservation among relevant Salmo-
nella serovars and cross-protection of serovar Typhi antigens
against serovar Typhimurium challenge infection, suggested that
some of these antigens might help to pave the way for a broadly
protective vaccine against systemic Salmonella infection. In addi-
tion, our findings suggested that surface-associated antigens might
represent particular promising antigens for both humoral and
cellular immunity to Salmonella, since recognition of surface
antigens uniquely enables detection and destruction of live
Salmonella in relevant host microenvironments. This crucial
importance of antigen localization could facilitate discovery of
additional protective antigens for Salmonella and potentially other
intracellular pathogens.
Materials and Methods
Ethics statement
All animal experiments were approved (license 2239, Kanto-
nales Veterina¨ramt Basel-Stadt) and performed according to local
guidelines (TschV, Basel) and the Swiss animal protection law
(TschG).
Cloning, expression, and purification of Salmonella
antigens
Antigens were PCR-amplified from Salmonella enterica serovar
Typhi Ty2 (or Salmonella enterica serovar Typhimurium SL1344
[58] for ompD), cloned as His6-fusions by conventional ligation into
pET22b, or by Enzyme Free Cloning into plasmid pLICHIS [83],
and overexpressed in E. coli BL21. GFP_His6 was cloned as
control antigen. Antigens were purified from washed inclusion
bodies using immobilized metal ion affinity chromatography
(Protino Ni TED 1000, Macherey Nagel) followed by ion
exchange chromatography (Ion exchange spin columns, Pierce
Thermo Scientific, cationic or anionic resins depending on antigen
isoelectric point).
Proteome analysis of ex vivo sorted Salmonella
Salmonella expressing the green fluorescent protein (GFP) were
sorted infected using flow cytometry as described [22]. Preparation
of tryptic peptides and analysis by LC-MS/MS was done essentially
as described [84] with some modifications. Given the limited sample
material Protein LoBind tubes and pipette tips (Axygen) were used
throughout the procedure. Frozen FACS sorted Salmonella pellets
were resuspended in 15 ml lysis buffer (100 mM ammonium
bicarbonate, 8 M urea, 0.1% RapiGest) and sonicated for
2630 seconds. The released proteins were reduced and alkylated,
and first digested for 4 hrs with sequencing grade LysC peptidase
(10 ng/ml; Promega) before overnight trypsin digestion. The
detergent was cleaved by adding 2M HCL and 5% TFA to final
concentrations of 50 mM and 0.5% respectively, and incubating for
45 min at 37uC. Prior to centrifugation to remove the cleaved
detergent (14,0006g, 10 min, 4uC) a mixture containing 32 heavy
labeled reference peptides were added to the samples (5*1025
fmoles per Salmonella for expected ‘‘high’’ abundance proteins,
5*1026 fmoles per Salmonella for expected ‘‘low’’ abundance
proteins; Tab. S1). The recovered peptides were desalted on C18
reverse-phase spin columns (Macrospin columns, Harvard appara-
tus), dried under vacuum and subjected to LC-MS/MS using an
LTQ-Orbitrap-Velos instrument (Thermo-Fischer Scientific). The
amount of material analyzed in a single shot in the MS depended on
the infection load, and corresponded to peptides derived from
between 5*105 and 2*106 sorted Salmonella, plus contaminating
mouse material which escaped detection in the cell sorter [22]. We
analyzed samples from seven independently infected mice. In order
to increase the number of Salmonella protein identifications, MS-
sequencing was focused on previously identified peptides from
Salmonella using the recently developed inclusion list driven workflow
[84]. Each sample was analyzed twice in succession in the MS to
verify technical reproducibility. Peptides and proteins were database
searched against a decoy database consisting of the SL1344 genome
sequence (ftp://ftp.sanger.ac.uk/pub/pathogens/Salmonella/),
GFP_OVA, 204 frequently observed contaminants, all mouse
entries from SwissProt (Version 57.12), and all sequences in reversed
order (total 42502 entries) using the Mascot search algorithm. The
search criteria were set as follows: full tryptic specificity was required
(cleavage after lysine or arginine residues); 2 missed cleavages were
allowed; carbamidomethylation (C) was set as fixed modification;
oxidation (M) as variable modification. The mass tolerance was set
to 10 ppm for precursor ions and 0.5 Da for fragment ions. The
false discovery rate was set to 1% for protein and peptide
identifications. In addition to Salmonella proteins a substantial
number of mouse proteins were identified in the samples as
previously noted [22]. Absolute quantities were determined for
those 18–20 ‘‘anchor’’ proteins that were detected along with a
corresponding labeled AQUA peptide using the Trans-Proteomic
Pipeline (TPP,V4.4.0). We then used the iBAQ method [40] to
establish absolute quantities of all remaining protein identifications,
with a linear model error of between 47 and 60%.
Construction of ovalbumin-expressing Salmonella
Translational fusions of the ovalbumin peptide containing
amino acids 319 to 343 to various proteins with differential
targeting in the Salmonella cell were constructed by PCR cloning.
All fusion genes were cloned into a pBR322-derived plasmid
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backbone [53] downstream of a Salmonella genome fragment
containing the in vivo inducible pagC promoter [57] and ribosomal
binding site 1 (AAGAA) or 2 (AGCAG) for low or high translation
initiation efficiencies [12]. To generate ova_aida, coding sequence
for the ovalbumin peptide (ova) was inserted between the signal
peptide derived from cholera toxin B and the HA tag in plasmid
pLAT260 [85]. A control plasmid coding for CTB_AIDA and
GFP_OVA was also constructed. To generate lpp_ova, lpp without
the C-terminal lysine codon that can cross-link to peptidoglycan
[86], was amplified from E. coli DH5a and fused with ova and a C-
terminal HA tag. To generate ova_mglB, mglB gene without the
signal peptide sequence was amplified from E. coli DH5a and fused
with a ctB signal sequence followed by ova and the HA tag. The
construction of gfp_ova has been described [87]. The various
plasmids were transformed into attenuated Salmonella enterica
serovar Typhimurium aroA SL3261 [58].
Biochemical analysis
Ovalbumin expression was assessed by western blotting with a
polyclonal antibody to ovalbumin (Sigma) that recognizes the OVA
peptide comprising amino acids 319 to 343 [53]. Salmonella outer
membranes were prepared by extraction with L-lauryl sarcosinate
as described [85]. Periplasm was prepared by chloroform extraction
as described [88]. Culture supernatants were sterile filtered (0,2 mm
pore size) and subjected to TCA precipitation [89]. To assess
ovalbumin surface accessibility, intact or lysed Salmonella cells were
treated with 50 mg ml21 trypsin at 37uC for 10 min. In addition,
Salmonella were stained with an antibody to the HA tag, and
examined by fluorescence microscopy.
Immune responses in convalescent mice
Female 8 to 12 weeks old 129/Sv mice were obtained from
Charles River. Mice were orally infected with 109 CFU Salmonella
enterica serovar Typhimurium SL1344 [58] from late log cultures
using a round-tip stainless steel needle. Control mice were sham-
infected. Mice were sacrificed 6 months after infection. Splenocytes
were isolated and tested for antigen-specific CD4 T cell responses as
described [41]. Unstimulated T cells from convalescent mice as well
as antigen-stimulated T cells from naı¨ve control mice showed only
weak background responses (Fig. S1). Some antigens gave also weak
responses for T cells from convalescent mice (depending on the
individual mouse). Together, these data suggested that antigen-
nonspecific background responses to E. coli contaminants that might
have been present in trace amounts in our antigen preparations did
not result in unspecific T cell responses in our assay. Plasma was
tested for antigen-specific IgG responses using ELISA with an IgG
calibration curve for absolute quantification.
Immunization and challenge experiments
Female, 8 to 12 weeks old BALB/c mice were obtained from
Charles River. Groups of 5 mice were immunized subcutaneously
with 10 mg antigen emulsified in complete Freund’s adjuvant
followed by a second immunization with incomplete Freund’s
adjuvant four weeks later. After additional four weeks, mice were
orally infected with 66105 CFU Salmonella enterica serovar
Typhimurium SL1344 [58] from late log cultures using a round-
tip stainless steel needle. Infected BALB/c were monitored twice
daily and sacrificed when moribund.
Ovalbumin-specific CD4 T cell responses
BALB/c and DO11.10 mice [51] were bred in the Bundesamt
fu¨r gesundheitlichen Verbraucherschutz und Veterina¨rmedizin
(Berlin, Germany) under specific-pathogen free conditions. Adop-
tive transfer of 46106 DO11.10 T cells into syngenic age- and sex-
matched BALB/c mice was performed one day before infection as
described [53]. For infection, attenuated Salmonella strains carrying
expression cassettes for various ovalbumin fusion proteins were
grown to late log phase and harvested. Bacteria were washed twice
and resuspended in LB containing 3% sodium bicarbonate. Doses
containing ca. 1010 cfu in 100 ml were administered intragastri-
cally to chimeric mice with a round-tip stainless steel needle. At
various time points post infection, mice were anesthetized and
sacrificed. DO11.10 T cell blast formation was determined by flow
cytometry as described [53]. Aliquots of the same Peyer’s patch
preparations were treated with 0.1% Triton x-100 to release
intracellular Salmonella for CFU determination by plating, and for
quantitation of GFP_OVA in vivo expression levels by two-color
flow cytometry as described [87]. Many TCR tg models show
substantial clonal expansion upon antigen stimulation. However,
in our Salmonella model we observe only weak and variable
accumulation of tg CD4 T cells in infected tissues which might
reflect the fact that even at peak Salmonella loads only about 1 ng
antigen is present [87]. Instead, blastogenesis as measured by
CD69 upregulation and increased forward scatter provides a
sensitive antigen-specific readout.
Detection of intact Salmonella in infected tissues
BALB/c mice with Salmonella loads of 106 to 107 in spleen and
liver were sacrificed. 10 mm cryosections were stained with
polyclonal rabbit antibodies to Salmonella lipopolysaccharide
(SIFIN) and anti-CD68 (abcam) followed by Alexa 546-conjugated
goat anti-rabbit and Alexa 647-conjugated goat anti-rat antibodies
(Invitrogen). Sections were examined by confocal microscopy
(Leica, SP5).
Structural models and epitope prediction
Structural models for selected Salmonella outer membrane
antigens based on solved structures of homologues were obtained
from SWISS-MODEL [90] available at http://swissmodel.expasy.
org. Linear B-cell epitopes were predicted using FBCPred [91]
available at http://ailab.cs.iastate.edu/bcpreds/predict.html using
an epitope length of 14 and 90% specificity. Peptides that bind to
MHC II I-Ad and/or I-Ed were predicted using RANKPEP [92]
available at http://imed.med.ucm.es/Tools/rankpep.html with a
binding threshold yielding 85% sensitivity for detection of well-
defined epitopes in MHCII haplotype databases (the default
setting of RANKPEP).
Supporting Information
Figure S1 Representative antigen-specific CD4 T cell
responses in convalescent and control mice. Cells were
stimulated with various antigens (shown are examples for T2461 and
T0937). CD4, CD154-double positive cells representing responding
cells were gated (upper panels) and analyzed for IFNc and IL-17
(lower panels). Background responses in control mice were subtracted
form responses in convalescent mice and reported in Tab. 1.
(TIF)
Figure S2 Expression and localization of ovalbumin
epitope fusion proteins in Salmonella. A) Anti-ovalbumin
immunoblot of total Salmonella cell lysates (36107 cfu) of strains
expressing either low (‘‘lo’’) or high (‘‘hi’’) levels of ovalbumin fused
to different proteins. Expected molecular weights were: GFP_OVA,
30 kDa; OVA_MglB, 38 kDa; Lpp_OVA, 11 kDa; OVA_AIDA,
67 kDa. B) Localization of various fusion proteins. OVA_MglB was
detected in isolated periplasm fractions (Ppl.) in similar quantities as
in whole cell lysates (Lys.). Lpp_OVA was detected in isolated outer
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membrane fractions. It was unaccessible for trypsin degradation in
intact Salmonella but readily digestible in isolated membrane
fractions. Immunostaining of intact Salmonella with a fluorescent
antibody showed no detectable signal. OVA_AIDA was detected in
isolated outer membranes and accessible to trypsin digestion even in
intact Salmonella suggesting surface localization. This was confirmed
by immunostaining. C) Immunoblot of culture supernatants of
4.561011 CFU (TCA precipitation). Endogenous Salmonella pro-
teins with apparent molecular weights of ca. 23 and 67 kDa,
respectively, cross-react with the anti-ovalbumin polyclonal anti-
body (empty arrowheads). These bands were also detected in non-
recombinant Salmonella. In addition, an OVA-containing protein of
around 11 kDa was released from Lpp_OVA expressing Salmonella
(black arrowhead), whereas a 30 kDa fragment was released from
Salmonella expressing high amounts of OVA_AIDA.
(TIF)
Table S1 List of isotope labeled peptides used for
protein quantification.
(XLS)
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2.2.3 Additional Results 
Supplementary Figure 1 (Fig S1) 
Representative antigen-specific CD4 T cell responses in convalescent and control 
mice. 
Cells were stimulated with various antigens (shown are examples for T2461 and 
T0937). CD4, CD154-double positive cells representing responding cells were gated 
(upper panels) and analyzed for IFNγ and IL-17 (lower panels). Background 
responses in control mice were subtracted form responses in convalescent mice and 
reported in Tab. 1.
Figure S1 
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Supplementary Figure 2 (Fig S2)
Expression and localization of ovalbumin epitope fusion proteins in Salmonella.
A) Anti-ovalbumin immunoblot of total Salmonella cell lysates (3×107 cfu) of strains
expressing either low (“lo”) or high (“hi”) levels of ovalbumin fused to different 
proteins. Expected molecular weights were: GFP_OVA, 30 kDa; OVA_MglB, 38 
kDa; Lpp_OVA, 11 kDa; OVA_AIDA, 67 kDa. B) Localization of various fusion 
proteins. OVA_MglB was detected in isolated periplasm fractions (Ppl.) in similar 
quantities as in whole cell lysates (Lys.). Lpp_OVA was detected in isolated outer 
membrane fractions. It was unaccessible for trypsin degradation in intact Salmonella
but readily digestible in isolated membrane fractions. Immunostaining of intact 
Salmonella with a fluorescent antibody showed no detectable signal. OVA_AIDA was 
detected in isolated outer membranes and accessible to trypsin digestion even in intact 
Salmonella suggesting surface localization. This was confirmed by immunostaining. 
C) Immunoblot of culture supernatants of 4.5×1011 CFU (TCA precipitation).
Endogenous Salmonella proteins with apparent molecular weights of ca. 23 and 67 
kDa, respectively, cross-react with the anti-ovalbumin polyclonal antibody (empty 
arrowheads). These bands were also detected in non-recombinant Salmonella. In 
addition, an OVA-containing protein of around 11 kDa was released from Lpp_OVA 
expressing Salmonella (black arrowhead), whereas a 30 kDa fragment was released 
from Salmonella expressing high amounts of OVA_AIDA. 
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Figure S2 
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3. Discussion
The discussion of the thesis is divided into two parts (Part A and Part B). 
Part A: Discussion on the identification of suitable targets to eradicate persisting   
Salmonella (refer to section 3.1). 
Part B: Discussion on the identification of predictive antigen properties that could 
help to develop a safe, enteric fever vaccine (refer to section 3.2). 
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Discussion 
3.1 Part A - Identification of suitable targets to eradicate persisting 
Salmonella 
Chronic infections pose a major obstacle for the treatment of infectious diseases. 
Complete eradication requires long–term chemotherapy causing poor patient 
compliance, emergence of antibiotic resistance, and failures to prevent relapse of the 
disease. Chronic infections are caused by persistent bacteria that are often drug 
tolerant, and may have limited or no replication and metabolic activities. As a 
consequence, most of the common antibiotics that target replicating bacteria fail to 
cure persistent infections. Hence, new targets for antibiotic development against 
persistent bacteria are required, but it is unclear if persisters have any essential 
maintenance requirements for survival that could provide opportunities for eradication 
through antimicrobial chemotherapy.
Indeed, the lack of well defined targets has been a major obstacle in the development 
of new antimicrobials against chronic infections [69]. On the other hand, few
individual maintenance function requirements have been suggested in various 
pathogens like Mycobacterium tuberculosis, E.coli etc [73, 81, 83]. However, 
experimental evidence directly supporting these predictions is fragmentary and 
inconsistent because suitable in vivo models required for such studies are largely 
lacking. 
Few in vivo models have actually been developed for M. tuberculosis, but it is 
controversial how well these models mimic relevant conditions during chronic 
infections [54]. For pathogens other than M. tuberculosis, there are no validated 
models to study persistency in vivo, representing a major challenge for drug 
development [136]. 
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In this study, we established a practical in vivo Salmonella mouse infection model in 
which Salmonella with metabolic and virulence defects persisted at constant tissue 
loads. In this model, Salmonella subpopulation even survived chronic treatment with 
floroquinolone, the most potent antibiotic to eradicate persistent salmonellosis 
indicating stringency of our model. The Salmonella metabolic network contains more 
than 1200 different enzymes that could all represent potential antimicrobial targets. 
However, even during acute infection, only a very small fraction of these enzymes are 
important for Salmonella physiology and could thus qualify as potentially suitable targets 
[137]. So, persisters being antibiotic tolerant, and metabolically less active might shrink 
the list of potential targets even further. Evaluation of twelve major Salmonella defects 
revealed extremely relaxed requirements confirming limited targets for antimicrobial 
chemotherapy of chronic Salmonella infections. On the other hand, we identified few 
novel candidates that might be explored for their suitability to control chronic 
infections. In particular, a defect in the unsaturated fatty acid resulted in rapid 
clearance of Salmonella suggesting that this pathway might contain promising targets 
for antibiotic therapy. Requirement of unsaturated fatty acid synthesis suggests 
continuous internal turnover, damage, and/or loss of the membrane to the environment 
during persistency. Damage/loss of the membrane has been already proposed as a 
potential target for treating persistent infections [138]. As an alternate mechanism, 
membranes could also be continuously lost through shedding of outer membrane 
vesicles [139]. However, our data indicated that lipopolysaccharide synthesis (outer 
membrane component of Salmonella) may not be needed during persistence. Further 
studies are required to clarify the function of fatty acid synthesis during Salmonella
persistency. 
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Interestingly, a study indicated that major gram–positive pathogens overcome growth 
inhibition by antimicrobials targeting the FASII (fatty acid synthesis type II present 
only in bacteria) pathway when unsaturated fatty acids are available from the host. 
Hence, it is important to note that both saturated and unsaturated host fatty acid might 
be sufficiently available in other infectious disease models especially for extracellular 
pathogens[140]. 
Additional targets for antimicrobial chemotherapy of chronic salmonellosis could be 
rapidly tested with our model. However, our data revealed extensive robustness of 
persisting Salmonella against perturbation suggesting a very limited target space 
(Fig 8). Possibly, target combinations might help to break the redundancy for persister 
survival but this remains to be tested in further studies. 
To summarize, we have established a practical, highly stringent, in vivo persistency 
model that enabled us to test a number of promising target candidates. However, the 
data revealed that it is clearly very difficult to find suitable targets because persisting 
Salmonella had very limited maintenance requirements. On the other hand, our results 
also revealed few candidates that might be further analyzed for their suitability to 
control chronic infections. 
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Figure 8. Targets against persistency. Picture showing most of the activities that are dispensable 
during persistency (deep red). Few genes had moderate persistent phenotype (light red). Only 
unsaturated fatty acid (fabB) synthesis had a more promising phenotype. 
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Discussion 
3.2 Part B - Identification of predictive antigen properties that could help to 
develop safe, enteric fever vaccine
Enteric fever remains a significant cause of human death and disease throughout large 
areas of the world. Adding to the public health problem posed by enteric fever has 
been the increasing antibiotic resistance, and the emergence of Salmonella serovars 
that are not covered by currently available vaccines. Hence, there is an urgent need to 
develop a new vaccine with broad serovar coverage [1]. 
Both, humoral and CD4+ T cell mediated immune response are required for protection
against virulent Salmonella [125]. Vaccine development has been hampered by the 
slow, largely empirical search for protective antigens. The major challenge is the 
identification of protective antigens among thousands of candidates predicted from 
the genome sequences. However, protective antigens are generally rare, and antigen 
properties that are relevant for T cell recognition remain poorly uncharacterized [128].
Promising antigens could be identified by mass immunization/challenge experiments. 
Indeed, this approach was used to screen one hundred randomly selected antigens as 
DNA vaccines against Leishmania major infection [141]. However, this approach 
revealed only very few protective antigens, and required extensive animal 
experimentation. Alternatively, suitable antigen properties might facilitate 
prioritization of promising candidates. Antigen properties such as in vivo expression 
levels, sequence-based antigenicity, immunodominance in covalescent individuals, 
and antigen localization have previously been proposed to prioritize vaccine 
candidates. However, the relevance of these antigen properties for protective 
immunity to Salmonella remained unclear because Salmonella antigens with 
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differential properties have not yet been systematically compared in 
immunization/challenge experiments.  
In this study, we did such experiments to determine relevant antigen properties in a 
Salmonella infected mouse typhoid fever model. 
We compared 37 in vivo expressed Salmonella antigens for immunogenicity and 
protectivity in a mouse typhoid fever model. We identified two novel surface 
associated antigen candidates (IroN and CirA) that enabled prolonged survival in the 
immunization/challenge experiment. On the other hand, all identified antigens were 
only partially protective against challenge infection with virulent Salmonella 
suggesting a need for identification of more antigens. Unfortunately, among 37 tested 
in vivo expressed antigens that were highly immunogenic during infection, only five 
conferred protection reflecting that protective Salmonella antigens might be very rare. 
The results revealed that previously proposed antigen properties including high in vivo
expression levels, immunodominance in covalescent individuals, and sequence based 
antigenicity failed to protect protective antigens. On the other hand, surface 
association appeared to be absolutely critical for antigen protectivity in contrast to the 
other antigen properties.
Antigen prioritization with relevant antigen properties might help to focus on a small 
number of promising candidates. In many infectious diseases, surface associated 
antigens are preferred as vaccine candidates. Several studies have suggested that 
surface associated model antigens might have higher immunogenicity compared to the 
internal model antigens [142, 143]. Indeed, our ovalbumin model also suggested 
superior immunogenicity of highly expressed surface antigens compared to the 
internal ones. However, these results were in marked contrast to humoral and cellular 
immune responses to autologous Salmonella antigens in covalescent mice. 
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Furthermore, the protective antigens were not immunodominant. These data clearly 
indicated that protective surface associated Salmonella antigens were not more 
immunogenic than internal antigens. However, surface associated antigens might have 
the advantage that they can be readily accessible for immune recognition compared to 
the internal antigens which are only released after the pathogen has been killed and 
degraded. Recognition of surface exposed antigens might thus be necessary to detect 
and kill live Salmonella that shield their internal antigens.
To conclude, our study identified novel Salmonella antigens that conferred partial 
protection against virulent Salmonella challenge. This might help to pave the way for 
protective vaccines against systemic Salmonella infection with broad serovar 
coverage. Additionally, our data also suggested a strategy for identification of 
protective Salmonella antigens that might be also relevant for other intracellular 
pathogens like Mycobacteria, Chlamydia, Listeria etc [144] that require both humoral 
and cellular immunity for protection.  
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The discussion (Part A and Part B) was mainly focussed on the two research 
publications. 
In part A, I focussed on the results in Research publication I: Extensive in vivo 
resilience of persistent Salmonella. 
In part B, I discussed about the data obtained in Research publication II: Immunity to 
intracellular Salmonella depends on surface associated antigens. 
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4. Appendix
4.1 Abbreviations 
ATP  Adenosine triphosphate 
B cell  B lymphocyte 
CD4+ T cell T cells expressing CD4 protein on their surface. 
CD8+ T cell T cells expressing CD8 protein on their surface. 
DFI Differential fluorescence induction 
E. coli  Escherechia coli 
E. faecalis Escherechia faecalis 
FAS II  Fatty acid synthesis type II 
IgA Immunoglobulin A 
IgM  Immunoglobulin B 
IVET  In vivo expression technology 
IVIAT  In vivo induced antigen technology 
LPS  Lipopolysaccharide 
M cells Microfold cells  
M. bovis Mycobacterium bovis
M. tb  Mycobacterium tuberculosis 
MDR  Multidrug–resistant 
MHC  Major histocompatibility complex 
Nramp Natural resistance associated macrophage protein 
NTS  Non-typhoidal salmonellosis 
SCID  Severe combined immunodeficiency 
S. typhi Salmonella enterica serovar typhi 
S. typhimurium Salmonella enterica serovar typhimurium 
SERPA Serological proteome analysis 
SPI 1  Salmonella pathogenecity island 1 
SPI 2 Salmonella pathogenecity island 2 
STM Signature – tagged mutagenesis
T cell T lymphocyte 
TA Toxin antitoxin 
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TCA Tricarboxylic acid 
TCR T cell receptor 
Th T helper cell 
VBNC Viable but non culturable 
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